[
  {
    "objectID": "presentations.html",
    "href": "presentations.html",
    "title": "Presentations",
    "section": "",
    "text": "The Consequences of COVID-19 and Long Covid. [Webinar in English]\n\nIntroduction and Welcome\n\nTime: 00:00 - 00:06\nLisa Norén, GP and spokesperson\n\nThe Norwegian Corona Study and Long Covid (in Norwegian)\n\nTime: 00:06 - 00:38\nArne Søraas, M.D., PhD.\n\nPASC — more than fatigue. Increased risk of disease and death after COVID-19 and the effect of COVID vaccines\n\nTime: 00:38 - 01:10\nGunhild A. Nyborg, M.D., PhD, Exam. Oecon\n\nHealthcare usage and sick leave in 2023\n\nTime: 01:10 - 01:39\nRichard Aubrey White, PhD\n\nQ&A Session with Lisa Norén\n\nTime: 01:39 - 02:02"
  },
  {
    "objectID": "presentations.html#section",
    "href": "presentations.html#section",
    "title": "Presentations",
    "section": "",
    "text": "The Consequences of COVID-19 and Long Covid. [Webinar in English]\n\nIntroduction and Welcome\n\nTime: 00:00 - 00:06\nLisa Norén, GP and spokesperson\n\nThe Norwegian Corona Study and Long Covid (in Norwegian)\n\nTime: 00:06 - 00:38\nArne Søraas, M.D., PhD.\n\nPASC — more than fatigue. Increased risk of disease and death after COVID-19 and the effect of COVID vaccines\n\nTime: 00:38 - 01:10\nGunhild A. Nyborg, M.D., PhD, Exam. Oecon\n\nHealthcare usage and sick leave in 2023\n\nTime: 01:10 - 01:39\nRichard Aubrey White, PhD\n\nQ&A Session with Lisa Norén\n\nTime: 01:39 - 02:02"
  },
  {
    "objectID": "presentations.html#section-1",
    "href": "presentations.html#section-1",
    "title": "Presentations",
    "section": "2024",
    "text": "2024\n\nLeve med ME podcast\nCovid er ikke over — long covid er den usynlige helsekrisen som få snakker om. I denne episoden møter vi Richard Aubrey White, statistiker og smittevernforsker, som deler sine erfaringer og innsikt i hva long covid betyr for enkeltmennesker og samfunnet. Hvorfor er helsefagarbeidere, lærere og familier spesielt utsatt? Hva kan vi gjøre for å redusere risikoen? Og hvordan vil helsevesenet se ut om 10 år dersom vi ikke handler nå? Bli med på en viktig samtale om en sykdom som påvirker langt flere enn du tror. [Podcast]\n\n\nNorges Myalgisk Encefalopati Forening\nHelsetjenestebruk og sykefravær i 2023 sammenlignet med trender før pandemien i Norge\n\n\n\nNasjonal kompetansetjeneste for CFS/ME\nTraces of COVID-19 on primary healthcare consultations and medically certified sick leave in 2023. [pdf]\n\n\nUppsala University\nPractical data management for modern open science. [pdf]\n\n\nR/Medicine\norg + plnr: Packages for Organized Project Material and Effective Analysis. [pdf]"
  },
  {
    "objectID": "presentations.html#section-2",
    "href": "presentations.html#section-2",
    "title": "Presentations",
    "section": "2023",
    "text": "2023\n\nNorthern European Symposium on Automated Surveillance\nCore Surveillance 9 as a framework for real-time analysis and disease surveillance, using NorSySS as an example. [pdf]\n\n\nUkrainian Symposium on Syndromic Surveillance\nThe Role of Statistics in Syndromic Surveillance. [pdf]"
  },
  {
    "objectID": "recipe/white-bread/white-bread.html",
    "href": "recipe/white-bread/white-bread.html",
    "title": "White Bread",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n2h\n\n\nCooking time\n40min\n\n\nServes\nXXkg loaf of bread\n\n\n\n\nIngredients\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nDough\nWater\n350g\n\n\n\nYeast\n10g\n\n\n\nFlour\n500g\n\n\n\nSalt\n10g\n\n\n\n\n\nInstructions\n\nCombine all ingredients.\nKnead.\nCover and leave to rise until doubled in size.\nKnead, shape, and place in pan.\nLeave to rise until doubled in size.\nPlace covered in oven and fan-bake at 180C for 40 minutes."
  },
  {
    "objectID": "recipe/palak-paneer/palak-paneer.html",
    "href": "recipe/palak-paneer/palak-paneer.html",
    "title": "Palak Paneer",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n30min\n\n\nCooking time\n45min\n\n\nServes\nSix people"
  },
  {
    "objectID": "recipe/palak-paneer/palak-paneer.html#pudding",
    "href": "recipe/palak-paneer/palak-paneer.html#pudding",
    "title": "Palak Paneer",
    "section": "Pudding",
    "text": "Pudding\n\nSift together flour, bicarb soda, and salt.\nBeat sugar and eggs until light and fluffy.\nAdd apricot jam and beat well.\nIn a saucepan, melt the butter.\nAdd the vinegar and milk.\nFold in the flour and egg mixtures alternatively.\nPour into a greased baking tray.\nBake at 180C for 45 minutes."
  },
  {
    "objectID": "recipe/palak-paneer/palak-paneer.html#sauce",
    "href": "recipe/palak-paneer/palak-paneer.html#sauce",
    "title": "Palak Paneer",
    "section": "Sauce",
    "text": "Sauce\n\nPlace all ingredients into a saucepan.\nStir over moderate heat until butter has melted and the sugar dissolved.\nPierce pudding with skewer and pour sauce over hot pudding."
  },
  {
    "objectID": "recipe/palak-paneer/palak-paneer.html#serving",
    "href": "recipe/palak-paneer/palak-paneer.html#serving",
    "title": "Palak Paneer",
    "section": "Serving",
    "text": "Serving\n\nGarnish with fresh mint leaves.\nServe hot or cold with cream or custard."
  },
  {
    "objectID": "recipe/hummus/hummus.html",
    "href": "recipe/hummus/hummus.html",
    "title": "Hummus",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n12-24h\n\n\nCooking time\n1,5h\n\n\nServes\nXXkg loaf of bread\n\n\n\n\nIngredients\n\n\n\nPurpose\nIngredient\nQuantity\n\n\n\n\nHummus\nChickpeas\n200g\n\n\n\nWater\n125mL\n\n\n\nBaking soda\n1/2 tablespoon\n\n\n\nGarlic\n2 cloves\n\n\n\nTahini paste\n100g\n\n\n\nCumin (powder)\n1/4 teaspoon\n\n\n\nPaprika\n1/2 teaspoon\n\n\n\nSalt\n1/2 teaspoon\n\n\n\nLemon juice\n1 tablespoon\n\n\n\nOlive oil\n1 tablespoon\n\n\n\n\n\nInstructions\nTest"
  },
  {
    "objectID": "recipe/challah/challah.html",
    "href": "recipe/challah/challah.html",
    "title": "Challah",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n2h\n\n\nCooking time\n45min\n\n\nServes\nXXkg loaf of bread\n\n\n\n\nIngredients\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nDough\nWater\n160g\n\n\n\nYeast\n10g\n\n\n\nSugar\n40g\n\n\n\nFlour\n400g\n\n\n\nEgg (yolk)\n2 (40g)\n\n\n\nEgg (whole)\n1 (60g)\n\n\n\nOil\n37,5g\n\n\n\nSalt\n10g\n\n\n\n\n\nInstructions\n\nCombine all ingredients.\nKnead.\nCover and leave to rise until doubled in size.\nKnead, shape, and place in pan.\nLeave to rise until doubled in size.\nPlace covered in oven and fan-bake at 180C for 40 minutes."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "89 scientific articles (64 866 citations, 45 h-index)."
  },
  {
    "objectID": "publications.html#section",
    "href": "publications.html#section",
    "title": "Publications",
    "section": "2025",
    "text": "2025\n\n[89] Olsson, K. et al.  (2025). “A registry study on nonsyndromic craniosynostosis: Long-term associations with academic achievement”. In: Journal of Plastic, Reconstructive & Aesthetic Surgery 100, pp. 104–111. URL: https://www.rwhite.no/articles/2025-olsson.pdf.\n\n\n[88] Rø, G. et al.  (2025). “Estimating the trend of COVID-19 in Norway by combining multiple surveillance indicators”. In: PloS one 20.1, p. e0317105. URL: https://www.rwhite.no/articles/2025-ro.pdf."
  },
  {
    "objectID": "publications.html#section-1",
    "href": "publications.html#section-1",
    "title": "Publications",
    "section": "2024",
    "text": "2024\n\n[87] Buer, S. et al.  (2024). “Executive deficits after SARS-CoV-2 infection: A cross-sectional population study”. In: Brain, Behavior, & Immunity - Health 41, p. 100857. ISSN: 2666-3546. URL: https://www.rwhite.no/articles/2024-buer.pdf.\n\n\n[86] Gidén, K. et al.  (2024). “Remission or Persistence? A Prediction Tool to Identify Women at Risk for Long-Term Depressive Symptoms Postpartum”. In: Depression and Anxiety 2024.1, p. 7734542. URL: https://www.rwhite.no/articles/2024-giden.pdf.\n\n\n[85] Gleditsch, R. N. et al.  (2024). “Vaccine coverage among children born to immigrant parents in Norway, 2000–2020”. In: Vaccine 42.12, pp. 3049–3056. URL: https://www.rwhite.no/articles/2024-gleditsch.pdf.\n\n\n[84] Hyllestad, S. et al.  (2024). “Estimating the risk of gastrointestinal illness associated with drinking tap water in Norway: a prospective cohort study”. In: BMC Public Health 24.1, p. 2107. URL: https://www.rwhite.no/articles/2024-hyllestad.pdf.\n\n\n[83] Lyngstad, T. M. et al.  (2024). “Årsrapport 2023. Overvåkning av infeksjonssykdommer som smitter fra mat, vann og dyr, inkludert vektorbårne sykdommer”. In: Folkehelseinstituttet. URL: https://www.rwhite.no/articles/2024-lyngstad.pdf.\n\n\n[82] White, R. A. et al.  (2024). “Aberrations in medically certified sick leave and primary healthcare consultations in Norway in 2023 compared to pre-COVID-19-pandemic trends”. In: Archives of Public Health 82.1, p. 187. ISSN: 2049-3258. DOI: 10.1186/s13690-024-01411-4. URL: https://www.rwhite.no/articles/2024-white.pdf."
  },
  {
    "objectID": "publications.html#section-2",
    "href": "publications.html#section-2",
    "title": "Publications",
    "section": "2023",
    "text": "2023\n\n[81] Axfors, C. et al.  (2023). “Prepregnancy participation and performance in world’s largest cross-country ski race as a proxy for physical exercise and fitness, and perinatal outcomes: prospective registry-based cohort study”. In: BJOG: An International Journal of Obstetrics & Gynaecology. URL: https://www.rwhite.no/articles/2023-axfors.pdf.\n\n\n[80] Engebretsen, S. et al.  (2023). “Regional probabilistic situational awareness and forecasting of COVID-19”. In: PLOS Computational Biology 19.1, pp. 1-26. URL: https://www.rwhite.no/articles/2023-engebretsen.pdf.\n\n\n[79] Ruiz, P. L. et al.  (2023). “Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway”. In: Vaccine 41.2, pp. 323–332. URL: https://www.rwhite.no/articles/2023-ruiz.pdf."
  },
  {
    "objectID": "publications.html#section-3",
    "href": "publications.html#section-3",
    "title": "Publications",
    "section": "2022",
    "text": "2022\n\n[78] Banti, A. B. et al.  (2022). “How many of persistent coughers have pulmonary tuberculosis? Population-based cohort study in Ethiopia”. In: BMJ open 12.5, p. e058466. URL: https://www.rwhite.no/articles/2022-banti.pdf.\n\n\n[77] Karamanis, G. et al.  (2022). “Gender dysphoria in twins: a register-based population study”. In: Scientific Reports 12.1, pp. 1–8. URL: https://www.rwhite.no/articles/2022-karamanis.pdf.\n\n\n[76] Skaland, R. G. et al.  (2022). “Impacts of climate change on drinking water quality in Norway”. In: Journal of Water and Health 20.3, pp. 539–550. URL: https://www.rwhite.no/articles/2022-skaland.pdf.\n\n\n[75] Swanson, D. et al.  (2022). “A One Health real-time surveillance system for nowcasting Campylobacter gastrointestinal illness outbreaks, Norway, week 30 2010 to week 11 2022”. In: Eurosurveillance 27.43, p. 2101121. URL: https://www.rwhite.no/articles/2022-swanson.pdf.\n\n\n[74] Wickremesekera, S. et al.  (2022). “Sri Lanka Complex Emergency - Needs Assessment Report, October 2022”. In: International Federation of Red Cross and Red Crescent Societies. URL: https://www.rwhite.no/articles/2022-wickremesekera.pdf."
  },
  {
    "objectID": "publications.html#section-4",
    "href": "publications.html#section-4",
    "title": "Publications",
    "section": "2021",
    "text": "2021\n\n[73] Herrador, B. G. et al.  (2021). “Heavy weather events, water quality and gastroenteritis in Norway”. In: One Health 13, p. 100297. URL: https://www.rwhite.no/articles/2021-herrador.pdf.\n\n\n[72] Indremo, M. et al.  (2021). “Validity of the Gender Dysphoria diagnosis and incidence trends in Sweden: a nationwide register study”. In: Scientific reports 11.1, pp. 1–10. URL: https://www.rwhite.no/articles/2021-indremo.pdf.\n\n\n[71] Isbeih, M. et al.  (2021). “Gestational age recorded at delivery versus estimations using antenatal care data from the Electronic Maternal and Child Health Registry in the West Bank: a comparative analysis”. In: The Lancet 398, p. S31. URL: https://www.rwhite.no/articles/2021-isbeih.pdf.\n\n\n[70] Jenness, S. M. et al.  (2021). “Measles vaccine coverage among children born to Somali immigrants in Norway”. In: BMC Public Health 21.1, pp. 1–8. URL: https://www.rwhite.no/articles/2021-jenness.pdf.\n\n\n[69] Makris, G. D. et al.  (2021). “Sunshine, temperature and suicidal behaviour in patients treated with antidepressants: an explorative nested case–control study”. In: Scientific Reports 11.1, pp. 1–12. URL: https://www.rwhite.no/articles/2021-makris.pdf.\n\n\n[68] Nørgaard, S. K. et al.  (2021). “Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020”. In: Eurosurveillance 26.2, p. 2002023. URL: https://www.rwhite.no/articles/2021-norgaard.pdf.\n\n\n[67] Winje, B. A. et al.  (2021). “The risk of invasive pneumococcal disease differs between risk groups in Norway following widespread use of the 13-valent pneumococcal vaccine in children”. In: Microorganisms 9.8, p. 1774. URL: https://www.rwhite.no/articles/2021-winje.pdf."
  },
  {
    "objectID": "publications.html#section-5",
    "href": "publications.html#section-5",
    "title": "Publications",
    "section": "2020",
    "text": "2020\n\n[66] Bränn, E. et al.  (2020). “Inflammatory markers in women with postpartum depressive symptoms”. In: Journal of neuroscience research 98.7, pp. 1309–1321. URL: https://www.rwhite.no/articles/2020-brann.pdf.\n\n\n[65] Hauge, S. H. et al.  (2020). “Urbanization and preparedness for outbreaks with high-impact respiratory pathogens”. In: Norwegian Institute of Public Health. URL: https://www.rwhite.no/articles/2020-hauge.pdf.\n\n\n[64] Vestergaard, L. S. et al.  (2020). “Excess all-cause mortality during the COVID-19 pandemic in Europe–preliminary pooled estimates from the EuroMOMO network, March to April 2020”. In: Eurosurveillance 25.26, p. 2001214. URL: https://www.rwhite.no/articles/2020-vestergaard.pdf."
  },
  {
    "objectID": "publications.html#section-6",
    "href": "publications.html#section-6",
    "title": "Publications",
    "section": "2019",
    "text": "2019\n\n[63] Benedetti, G. et al.  (2019). “Identifying exceptional malaria occurrences in the absence of historical data in South Sudan: a method validation”. In: Public Health Action 9.3, pp. 90–95. URL: https://www.rwhite.no/articles/2019-benedetti.pdf.\n\n\n[62] Edwards, C. H. et al.  (2019). “Evaluating costs and health consequences of sick leave strategies against pandemic and seasonal influenza in Norway using a dynamic model”. In: BMJ open 9.4, p. e027832. URL: https://www.rwhite.no/articles/2019-edwards.pdf.\n\n\n[61] Henriksson, H. E. et al.  (2019). “Spring peaks and autumn troughs identified in peripheral inflammatory markers during the peripartum period”. In: Scientific reports 9.1, pp. 1–13. URL: https://www.rwhite.no/articles/2019-henriksson.pdf.\n\n\n[60] MacDonald, E. et al.  (2019). “The role of domestic reservoirs in domestically acquired Salmonella infections in Norway: epidemiology of salmonellosis, 2000–2015, and results of a national prospective case–control study, 2010–2012”. In: Epidemiology & Infection 147. URL: https://www.rwhite.no/articles/2019-macdonald.pdf.\n\n\n[59] Nielsen, J. et al.  (2019). “European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?” In: Clinical microbiology and infection 25.10, pp. 1266–1276. URL: https://www.rwhite.no/articles/2019-nielsen.pdf.\n\n\n[58] Salih Joelsson, L. et al.  (2019). “Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count”. In: PloS one 14.8, p. e0221015. URL: https://www.rwhite.no/articles/2019-salih.pdf.\n\n\n[57] Steens, A. et al.  (2019). “Indirect effects of pneumococcal childhood vaccination in individuals treated with immunosuppressive drugs in ambulatory care: a case-cohort study”. In: Clinical Infectious Diseases 68.8, pp. 1367–1373. URL: https://www.rwhite.no/articles/2019-steens.pdf.\n\n\n[56] Winje, B. A. et al.  (2019). “Immigrant screening for latent tuberculosis infection: numbers needed to test and treat, a Norwegian population-based cohort study”. In: BMJ open 9.1, p. e023412. URL: https://www.rwhite.no/articles/2019-winje.pdf."
  },
  {
    "objectID": "publications.html#section-7",
    "href": "publications.html#section-7",
    "title": "Publications",
    "section": "2018",
    "text": "2018\n\n[55] Henriksson, H. E. et al.  (2018). “Meteorological parameters and air pollen count in association with self-reported peripartum depressive symptoms”. In: European Psychiatry 54, pp. 10–18. URL: https://www.rwhite.no/articles/2018-henriksson.pdf.\n\n\n[54] Schein, Y. L. et al.  (2018). “Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study”. In: BMC infectious diseases 18.1, pp. 1–10. URL: https://www.rwhite.no/articles/2018-schein.pdf.\n\n\n[53] Weyde, K. V. et al.  (2018). “A longitudinal study of road traffic noise and body mass index trajectories from birth to 8 years”. In: Epidemiology (Cambridge, Mass.) 29.5, p. 729. URL: https://www.rwhite.no/articles/2018-weyde.pdf.\n\n\n[52] Winje, B. A. et al.  (2018). “Stratification by interferon-gamma release assay level predicts risk of incident TB”. In: Thorax 73.7, pp. 652–661. URL: https://www.rwhite.no/articles/2018-winje.pdf.\n\n\n[51] Wisløff, T. et al.  (2018). “Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies”. In: Journal of viral hepatitis 25.9, pp. 1066–1077. URL: https://www.rwhite.no/articles/2018-wisloff-feasibility.pdf.\n\n\n[50] Wisløff, T. et al.  (2018). “Economic evaluation of direct-acting antivirals for hepatitis C in Norway”. In: Pharmacoeconomics 36.5, pp. 591–601. URL: https://www.rwhite.no/articles/2018-wisloff-economic.pdf."
  },
  {
    "objectID": "publications.html#section-8",
    "href": "publications.html#section-8",
    "title": "Publications",
    "section": "2017",
    "text": "2017\n\n[49] Andreassen, A. E. S. et al.  (2017). “The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway”. In: Antimicrobial Resistance & Infection Control 6.1, pp. 1–8. URL: https://www.rwhite.no/articles/2017-andreassen.pdf.\n\n\n[48] Bränn, E. et al.  (2017). “Inflammatory markers in late pregnancy in association with postpartum depression—a nested case-control study”. In: Psychoneuroendocrinology 79, pp. 146–159. URL: https://www.rwhite.no/articles/2017-brann.pdf.\n\n\n[47] Decroo, T. et al.  (2017). “Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study”. In: BMJ open 7.8, p. e016800. URL: https://www.rwhite.no/articles/2017-decroo.pdf.\n\n\n[46] Edvinsson, Å. et al.  (2017). “Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction”. In: Psychoneuroendocrinology 80, pp. 15–25. URL: https://www.rwhite.no/articles/2017-edvinsson.pdf.\n\n\n[45] Makris, G. D. et al.  (2017). “Season of treatment initiation with antidepressants and suicidal behavior: A population-based cohort study in Sweden”. In: Journal of affective disorders 215, pp. 245–255. URL: https://www.rwhite.no/articles/2017-makris.pdf.\n\n\n[44] Meijerink, H. et al.  (2017). “Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030”. In: BMC infectious diseases 17.1, pp. 1–12. URL: https://www.rwhite.no/articles/2017-meijerink.pdf.\n\n\n[43] Vestergaard, L. S. et al.  (2017). “Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017”. In: Eurosurveillance 22.14, p. 30506. URL: https://www.rwhite.no/articles/2017-vestergaard.pdf."
  },
  {
    "objectID": "publications.html#section-9",
    "href": "publications.html#section-9",
    "title": "Publications",
    "section": "2016",
    "text": "2016\n\n[42] Agardh, E. E. et al.  (2016). “Alcohol-attributed disease burden in four Nordic countries: a comparison using the Global Burden of Disease, Injuries and Risk Factors 2013 study”. In: Addiction 111.10, pp. 1806–1813. URL: https://www.rwhite.no/articles/2016-agardh.pdf.\n\n\n[41] Bourne, R. R. A. et al.  (2016). “Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: a meta-analysis”. In: PloS one 11.10, p. e0162229. URL: https://www.rwhite.no/articles/2016-bourne.pdf.\n\n\n[40] Leasher, J. L. et al.  (2016). “Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010”. In: Diabetes care 39.9, pp. 1643–1649. URL: https://www.rwhite.no/articles/2016-leasher.pdf.\n\n\n[39] MacDonald, E. et al.  (2016). “Are the current notification criteria for Lyme borreliosis in Norway suitable? Results of an evaluation of Lyme borreliosis surveillance in Norway, 1995–2013”. In: BMC Public Health 16.1, pp. 1–11. URL: https://www.rwhite.no/articles/2016-macdonald.pdf.\n\n\n[38] Mitnick, C. D. et al.  (2016). “Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method”. In: European Respiratory Journal 48.4, pp. 1160–1170. URL: https://www.rwhite.no/articles/2016-mitnick.pdf.\n\n\n[37] Naidoo, K. S. et al.  (2016). “Global vision impairment and blindness due to uncorrected refractive error, 1990–2010”. In: Optometry and Vision Science 93.3, pp. 227–234. URL: https://www.rwhite.no/articles/2016-naidoo.pdf.\n\n\n[36] Vestrheim, D. F. et al.  (2016). “Geographical differences in seroprevalence of Borrelia burgdorferi antibodies in Norway, 2011–2013”. In: Ticks and tick-borne diseases 7.5, pp. 698–702. URL: https://www.rwhite.no/articles/2016-vestrheim.pdf.\n\n\n[35] Vos, T. et al.  (2016). “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015”. In: The lancet 388.10053, pp. 1545–1602. URL: https://www.rwhite.no/articles/2016-vos.pdf.\n\n\n[34] Wang, H. et al.  (2016). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015”. In: The lancet 388.10053, pp. 1459–1544. URL: https://www.rwhite.no/articles/2016-wang.pdf."
  },
  {
    "objectID": "publications.html#section-10",
    "href": "publications.html#section-10",
    "title": "Publications",
    "section": "2015",
    "text": "2015\n\n[33] Forns, J. et al.  (2015). “Perfluoroalkyl substances measured in breast milk and child neuropsychological development in a Norwegian birth cohort study”. In: Environment international 83, pp. 176–182. URL: https://www.rwhite.no/articles/2015-forns.pdf.\n\n\n[32] Iszatt, N. et al.  (2015). “Prenatal and Postnatal Exposure to Persistent Organic Pollutants and Infant Growth: A Pooled Analysis of Seven European Birth Cohorts”. In: Environmental Health Perspectives 123.7, p. 731. URL: https://www.rwhite.no/articles/2015-iszatt.pdf.\n\n\n[31] Khairallah, M. et al.  (2015). “Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010”. In: Investigative ophthalmology & visual science 56.11, pp. 6762–6769. URL: https://www.rwhite.no/articles/2015-khairallah.pdf.\n\n\n[30] MacDonald, E. et al.  (2015). “Risk factors for sporadic domestically acquired Campylobacter infections in Norway 2010–2011: A national prospective case-control study”. In: PLoS One 10.10, p. e0139636. URL: https://www.rwhite.no/articles/2015-macdonald.pdf.\n\n\n[29] Mandal, S. et al.  (2015). “Analysis of composition of microbiomes: a novel method for studying microbial composition”. In: Microbial ecology in health and disease 26.1, p. 27663. URL: https://www.rwhite.no/articles/2015-mandal.pdf.\n\n\n[28] Mathers, C. D. et al.  (2015). “Causes of international increases in older age life expectancy”. In: The Lancet 385.9967, pp. 540–548. URL: https://www.rwhite.no/articles/2015-mathers.pdf.\n\n\n[27] Ruiz, M. et al.  (2015). “Mother’s education and the risk of preterm and small for gestational age birth: a DRIVERS meta-analysis of 12 European cohorts”. In: J Epidemiol Community Health 69.9, pp. 826–833. URL: https://www.rwhite.no/articles/2015-ruiz.pdf.\n\n\n[26] Stevens, G. A. et al.  (2015). “Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys”. In: The Lancet Global Health 3.9, pp. e528–e536. URL: https://www.rwhite.no/articles/2015-stevens.pdf.\n\n\n[25] White, R. A. et al.  (2015). “Does suicide have a stronger association with seasonality than sunlight?” In: BMJ open 5.6, p. e007403. URL: https://www.rwhite.no/articles/2015-white-suicide.pdf.\n\n\n[24] White, R. A. et al.  (2015). “Projected treatment capacity needs in Sierra Leone”. In: PLoS currents 7. URL: https://www.rwhite.no/articles/2015-white-ebola.pdf."
  },
  {
    "objectID": "publications.html#section-11",
    "href": "publications.html#section-11",
    "title": "Publications",
    "section": "2014",
    "text": "2014\n\n[23] Bourne, R. R. A. et al.  (2014). “Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 629–638. URL: https://www.rwhite.no/articles/2014-bourne.pdf.\n\n\n[22] Jonas, J. B. et al.  (2014). “Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis”. In: American journal of ophthalmology 158.4, pp. 808–815. URL: https://www.rwhite.no/articles/2014-jonas-visual.pdf.\n\n\n[21] Jonas, J. B. et al.  (2014). “Prevalence and causes of vision loss in Central and South Asia: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 592–598. URL: https://www.rwhite.no/articles/2014-jonas-prevalence.pdf.\n\n\n[20] Keeffe, J. et al.  (2014). “Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 586–591. URL: https://www.rwhite.no/articles/2014-keeffe.pdf.\n\n\n[19] Khairallah, M. et al.  (2014). “Prevalence and causes of vision loss in North Africa and the Middle East: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 605–611. URL: https://www.rwhite.no/articles/2014-khairallah.pdf.\n\n\n[18] Leasher, J. L. et al.  (2014). “Prevalence and causes of vision loss in Latin America and the Caribbean: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 619–628. URL: https://www.rwhite.no/articles/2014-leasher.pdf.\n\n\n[17] Naidoo, K. et al.  (2014). “Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 612–618. URL: https://www.rwhite.no/articles/2014-naidoo.pdf.\n\n\n[16] Wong, T. Y. et al.  (2014). “Prevalence and causes of vision loss in East Asia: 1990–2010”. In: British Journal of Ophthalmology 98.5, pp. 599–604. URL: https://www.rwhite.no/articles/2014-wong.pdf."
  },
  {
    "objectID": "publications.html#section-12",
    "href": "publications.html#section-12",
    "title": "Publications",
    "section": "2013",
    "text": "2013\n\n[15] Bourne, R. R. et al.  (2013). “Causes of vision loss worldwide, 1990–2010: a systematic analysis”. In: The lancet global health 1.6, pp. e339–e349. URL: https://www.rwhite.no/articles/2013-bourne.pdf.\n\n\n[14] Miller, M. et al.  (2013). “Firearms and suicide in the United States: is risk independent of underlying suicidal behavior?” In: American journal of epidemiology 178.6, pp. 946–955. URL: https://www.rwhite.no/articles/2013-miller.pdf.\n\n\n[13] Stevens, G. A. et al.  (2013). “Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010”. In: Ophthalmology 120.12, pp. 2377–2384. URL: https://www.rwhite.no/articles/2013-stevens.pdf.\n\n\n[12] Størdal, K. et al.  (2013). “Early feeding and risk of celiac disease in a prospective birth cohort”. In: Pediatrics 132.5, pp. e1202–e1209. URL: https://www.rwhite.no/articles/2013-stordal.pdf.\n\n\n[11] White, R. A. et al.  (2013). “Novel developmental analyses identify longitudinal patterns of early gut microbiota that affect infant growth”. In: PLoS computational biology 9.5, p. e1003042. URL: https://www.rwhite.no/articles/2013-white.pdf."
  },
  {
    "objectID": "publications.html#section-13",
    "href": "publications.html#section-13",
    "title": "Publications",
    "section": "2012",
    "text": "2012\n\n[10] Bourne, R. R. et al.  (2012). “The Global Burden of Disease Study: the Impact of Vision Loss: prevalence and trends of blindness and visual impairment over the past 28 years”. In: Investigative Ophthalmology & Visual Science 53.14, pp. 3175–3175. URL: https://www.rwhite.no/articles/2012-bourne.pdf.\n\n\n[9] Fredrickson, M. J. et al.  (2012). “Randomized study of the effect of local anesthetic volume and concentration on the duration of peripheral nerve blockade”. In: Regional Anesthesia & Pain Medicine 37.5, pp. 495–501. URL: https://www.rwhite.no/articles/2012-fredrickson.pdf.\n\n\n[8] Lim, S. S. et al.  (2012). “A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2224–2260. URL: https://www.rwhite.no/articles/2012-lim.pdf.\n\n\n[7] Murray, C. J. et al.  (2012). “Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2197–2223. URL: https://www.rwhite.no/articles/2012-murray.pdf.\n\n\n[6] Stevens, G. A. et al.  (2012). “Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data”. In: The lancet 380.9844, pp. 824–834. URL: https://www.rwhite.no/articles/2012-stevens.pdf.\n\n\n[5] Vos, T. et al.  (2012). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. In: The lancet 380.9859, pp. 2163–2196. URL: https://www.rwhite.no/articles/2012-vos.pdf.\n\n\n[4] White, R. A. (2012). “Novel Statistical Methods Applied in Clinical Trials and Gut Microbiota”. URL: https://www.rwhite.no/articles/2012-white.pdf."
  },
  {
    "objectID": "publications.html#section-14",
    "href": "publications.html#section-14",
    "title": "Publications",
    "section": "2011",
    "text": "2011\n\n[3] Falzon, D. et al.  (2011). WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. URL: https://www.rwhite.no/articles/2011-falzon.pdf.\n\n\n[2] Fredrickson, M. J. et al.  (2011). “Low-volume ultrasound-guided nerve block provides inferior postoperative analgesia compared to a higher-volume landmark technique”. In: Regional Anesthesia and Pain Medicine 36.4, pp. 393–398. URL: https://www.rwhite.no/articles/2011-fredrickson.pdf.\n\n\n[1] White, R. et al.  (2011). “History of Military Service and the Risk of Suicidal Ideation: Findings From the 2008 National Survey on Drug Use and Health”. In: Suicide and Life-Threatening Behavior 41.5, pp. 554–561. URL: https://www.rwhite.no/articles/2011-white.pdf."
  },
  {
    "objectID": "post/2024-10-02-long-covid-is-common-and-often-permanent/long-covid-is-common-and-often-permanent.html",
    "href": "post/2024-10-02-long-covid-is-common-and-often-permanent/long-covid-is-common-and-often-permanent.html",
    "title": "Long Covid is Common and Often Permanent",
    "section": "",
    "text": "Published in Aftenposten the 2nd of October 2024.\n\n\nThis is a translation of the original Norwegian op-ed, and discrepancies may exist.\nIn an article in Aftenposten on September 27, Professor and Director Preben Aavitsland at the Norwegian Institute of Public Health (NIPH) claims that long covid is “rare and often resolves over time.”\nThis is incorrect — long covid is common and often permanent.\nAavitsland’s claim about duration likely stems from NIPH’s study, which only analyzes the number of general practitioner visits after COVID-19 infection. His interpretation — that fewer visits means the long covid is cured — is incorrect. People stop going to the doctor when the doctor can’t help them, even if the symptoms persist.\nCumulative Risk Increases\nA health-based COVID-19 study — which looked at health status rather than doctor visits — recently showed that COVID-19 led to a 6 percent risk of memory problems more than a year later in Norwegians without prior immunity. Vaccination and prior immunity are about 50 percent effective at preventing long covid, so the risk can be reduced to around 3 percent per infection for most people.\nThe cumulative risk after two infections is then 5.9 percent; after four infections, 11.5 percent; after six infections, 16.7 percent.\nThis is one example, but several studies show the same result — repeated infections increase cumulative risk to an unacceptable level. This must be seen in the context of today’s mass-infection strategy, where people are infected on average once a year.\nIt is no surprise that the rise in sick leave is driven by three diagnostic codes (A04, P02, and P29), all of which are associated with long covid.\nDownplaying the Burden\nThe mass-infection strategy was supported by NIPH’s risk assessments, which only considered acute COVID-19. The NIPH has never published a risk assessment of the strategy that includes long covid.\nIn light of the high rates of sick leave, likely due to long-term effects, those responsible for the strategy — and for the missing risk assessments — have strong incentives to downplay the burden long covid places on society.\nWe must prevent COVID-19 infections and long covid. This can be done by improving ventilation, using air purifiers, and recommending the use of FFP2 respirators when transmission is high.\nRichard Aubrey White holds a Ph.D. in biostatistics from Harvard University. White is a researcher at the Norwegian Institute of Public Health, but does not speak on behalf of the NIPH."
  },
  {
    "objectID": "post/2024-11-11-covid-er-farligere-enn-du-tror/covid-er-farligere-enn-du-tror.html",
    "href": "post/2024-11-11-covid-er-farligere-enn-du-tror/covid-er-farligere-enn-du-tror.html",
    "title": "Covid er farligere enn du tror",
    "section": "",
    "text": "Publisert på NRK den 11. november 2024.\n\n\nDa pandemien traff oss i 2020 visste vi lite om covid-19 og viruset som forårsaker denne helt nye sykdommen. Nå vet vi mye mer.\nDet har vist seg at koronaviruset nesten utelukkende smitter gjennom luften. Hvis du ikke puster inn viruset, blir du ikke smittet. Derfor merker mange covid som forkjølelse og hoste. Men etter at viruset er kommet inn gjennom luftveiene, sprer det seg videre til hele kroppen.\nHva koronaviruset gjør med kroppen\nEt virus består nesten bare av innpakket arvemateriale. For at viruset skal kunne formere seg, må det komme seg inn i kroppens celler. Viruset «snylter» på cellene våre for å lage mange nye kopier av seg selv.\n\n«Skader kan ses på hjernen, også etter mild sykdom»\n\nKoronaviruset har en ganske unik evne til å komme seg inn i mange ulike celletyper, inkludert cellene som danner innsiden av blodårene og immunceller, og skade dem. Derfor anses ikke covid å være en luftveisinfeksjon, men en såkalt systemisk, multiorgan infeksjonssykdom\nSamtidig som vaksiner og tidligere smitte har gjort akutt covid mindre farlig, har bekymringene for virusets mange senskader økt.\nForskning viser at risikoen for senskader øker jo mer alvorlig den akutte sykdommen er, men det er likevel flest tilfeller av senskader etter mild sykdom, fordi dette er så vanlig.\nHos noen pasienter med long covid er det vist at viruset kan forbli inne i kroppens celler og organer i lang tid. De klarer ikke helt å bli kvitt det. Da er det ikke overraskende at ny forskning finner at gener som styrer kroppens evne til å bekjempe virus er knyttet til økt risiko for long covid.\n\n«Plagene rammer mange, og er ofte vedvarende»\n\nDet er også sett at mus som får injisert antistoffer fra folk med long covid, får de symptomene som pasientene har. Det er derfor på høy tid at vi slutter å psykologisere disse plagene.\nØker risikoen for mange helseplager\nDet er rapportert skade på ti ulike organsystemer etter covid. Senskader etter covid er altså mer enn slitenhet og tung pust. Kognitive plager som «hjernetåke», nedsatt hukommelse, tempo og konsentrasjonsevne, og redusert evne til sammensatte handlinger er de symptomene som oftest rapporteres etter covid, og skader kan ses på hjernen ved MR, også etter mild sykdom.\nDet er bekymringsfullt at store studier, inkludert den norske Koronastudien, finner at disse plagene rammer mange, og er ofte vedvarende.\nRisikoen for å få en ny, helt annen sykdom, som diabetes type 1 og type 2 eller en infeksjonssykdom, og risikoen for å dø av alle årsaker, er også økt i flere år etter covid. Covid er funnet å være en egen risikofaktor for hjerte- og karsykdom, også hos tidligere friske. Disse sykdommene er også forbundet med økt behov for helsetjenester.\n\n«Det er flest tilfeller av senskader etter mild sykdom»\n\nØkt press på helsevesenet og trygdevesenet\nSelv om risikoen for senskader ble noe lavere etter at omikron kom og folk ble vaksinert, ser man fortsatt i studier med kontrollgrupper at 3 prosent eller mer får helseplager av varierende grad etter gjennomgått covid. Hver infeksjon innebærer en økt risiko.\nSå lenge vi ikke har mer effektive vaksiner eller medisinske behandlinger, kan vi derfor anta at antall nordmenn som har problemer med hukommelse, konsentrasjonsevne og evnen til å utføre komplekse oppgaver, vil øke i årene fremover. Med noen millioner koronainfeksjoner hvert år i Norge, utgjør dette et samfunnsproblem.\nNår så få tester seg, vet folk ofte ikke at de har hatt covid. Samtidig kan altså senskader dukke opp i form av annen sykdom, lenge etter at vi føler oss friske.\nI tillegg bruker allmennlegene i Norge et kodesystem for diagnoser som mangler en egen kode for senskader etter covid. Derfor vil mye av den økte syke- og dødeligheten som følger etter covid, bli registrert under helt andre diagnoser, som A04 (utmattelse) eller P29 (som inkluderer slitenhet). P29 sorterer under «lettere psykiske lidelser».\nLong covid er trolig årsak til et stort antall sykmeldinger med disse diagnosene, som vi vet er økt mye de siste to år.\n\n«Det er rapportert skade på ti ulike organsystemer»\n\nVi må forvente flere sykmeldte, et mer belastet helsevesen og kanskje høyere overdødelighet også i tiden fremover, slik vi har sett siden myndighetene sluttet å begrense smittespredningen i begynnelsen av 2022.\nSelv om antallet som blir alvorlig syke og dør av akutt covid synker, er altså sykdommen en driver bak denne utviklingen.\nHvordan forebygge?\nFor det første bør alle som kan ha covid, teste seg og unngå å smitte andre ved å holde seg hjemme hvis testen er positiv.\nDet er vist at vaksinene beskytter mot senskader, inkludert skader på hjerte-karsystemet, og den økte risikoen for sykdom og død. Senskader kan ramme alle aldersgrupper.\nVaksinene beskytter alle aldersgrupper, har få bivirkninger, og er godkjent for alle over seks måneder. Derfor bør alle tilbys grunnvaksinasjon og boostere hver gang det kommer nye, oppdaterte covid-vaksiner etter tilpassede opplegg for ulike grupper, slik amerikanske helsemyndigheter anbefaler.\n\n«Det er på høy tid at vi slutter å psykologisere disse plagene»\n\nMen beskyttelsen fra vaksinasjon er ikke fullgod, og effekten faller raskt etter et halvt års tid. Den eneste sikre måten å forebygge senskader etter covid er per i dag å unngå å bli smittet.\nSiden covid smitter gjennom luftveiene, blir vi ikke smittet hvis det ikke er viruspartikler i luften vi puster inn. Et munnbind som effektivt hindrer partiklene å nå frem til nese og munn, gir derfor god beskyttelse.\nDet er lurt å bruke munnbind ved høy smitterisiko, som når det er mye smitte i omløp og man er innendørs med mange andre, eller om noen er forkjølet.\nBedring av inneklima kan også redusere antall syke. Norge bør satse på å bedre ventilasjonen innendørs og installere luftrensere i skoler, offentlige bygg og arbeidsplasser, slik andre land gjør. Dette er vist å gi færre infeksjoner hos barnehage- og skolebarn, redusert sykefravær hos foreldre og ansatte, og det kan spare penger og øke livskvaliteten.\nÅ få covid annethvert år er bedre for helsen din enn å få covid to ganger hvert år. For hvert smittetilfelle vi forebygger, er det også færre som smitter videre. Derfor er slike forebyggende, enkle smitteverntiltak mer effektive enn mange tror, selv om de ikke er perfekte. De kan trolig spare samfunnet for store summer.\nRichard Aubrey White er forsker ved Folkehelseinstituttet, men skriver ikke på vegne av arbeidsgiveren."
  },
  {
    "objectID": "post/2024-09-27-forebygg-covid-19-forebygg-sykefravaer/forebygg-covid-19-forebygg-sykefravaer.html",
    "href": "post/2024-09-27-forebygg-covid-19-forebygg-sykefravaer/forebygg-covid-19-forebygg-sykefravaer.html",
    "title": "Forebygg covid-19, forebygg sykefravær",
    "section": "",
    "text": "Publisert i Dag of Tid den 27. september 2024.\n\n\nI innlegget «Ikke et spørsmål om moral, men om god behandling» i Dag og Tid 20. september hevder Marit Hermansen, sjeflege i Nav, at «det spiller ikke så stor rolle hva som er årsaken til at man opplever lettere psykiske lidelser. Enten årsaken er korona eller noe annet, vil svært mange tjene helsemessig på å være i tilpasset aktivitet og arbeid.»\nDette er feil.\nLitt bakgrunn: Sykefraværet har økt i flere diagnosekoder sammenlignet med 2019. Navs sykefraværsregister har ingen kode for senfølger av covid-19, dermed er personer med senfølger spredt over flere koder basert på symptomer. Senfølger av covid-19 kan påvirke nesten alle organsystemer, inkludert hjernen. De største økningene tilhører kodene A04 (utmattelse), P02 (psykisk ubalanse situasjonsbetinget) og P29 (psykiske symptomer/plager). Utmattelse har en tydelig tilknytning til senfølger av covid-19, likevel fokuserer narrativet kun på «lettere psykiske lidelser» (P02 og P29). Nav-forskerne Moberg og Kabashi har funnet at sykefravær på grunn av akutt covid-19 var assosiert med 25 % og 18 % høyere sykefravær for henholdsvis P02 og P29 i løpet av de påfølgende 12 ukene.\nIfølge WHO gir 1 av 10 koronainfeksjoner senfølger, og studier anslår at vaksiner kun er ca. 50 % effektive i å forebygge disse. Med dagens «fri smitte»-strategi har Norge hatt 5 millioner infeksjoner hvert år siden 2022. Ut fra dette kan vi forvente ca. 250 000 nye tilfeller med senfølger hvert år – også i 2024 og 2025. Den tyske helseministeren prof. Lauterbach uttalte den 17. september 2024: «Senfølger av covid-19 er ikke borte, og de vil ikke forsvinne. Det finnes ofte ingen kur for de som er rammet – og antallet rammede vokser.»\nDet er gode bevis for at en stor del av økningen i sykefraværet skyldes senfølger av covid-19.\nNå til Hermansens sak: God behandling må tilpasses sykdommens årsak. Dersom en person er utbrent på grunn av livs- eller arbeidsforhold, kan aktivitet hjelpe. Men hvis noen feildiagnostiseres som utbrent, mens de faktisk lider av senfølger av covid-19, kan aktivitet uten tilstrekkelig hensyn til anstrengelsesutløst sykdomsfølelse/symptomforverring (PEM) potensielt være skadelig.\nVi bør forebygge sykdom, ikke bare behandle den. Dersom økningen i sykefravær skyldes senfølger av covid-19, må vi forebygge covid-19. Dette kan gjøres ved å forbedre ventilasjon, øke luftrensing og anbefale bruk av FFP2-åndedrettsvern i offentlige rom når det er mye smitte. Disse tiltakene er effektive og påvirker ikke dagliglivet nevneverdig. Vi kan redusere selve problemet, og folk kan slippe å bli syke – det vi mangler, er vilje.\nTil slutt handler det om ansvar. Siden 2022 har landet, under Arbeiderpartiet og Senterpartiets regjering, ført en «fri smitte»-politikk uten en risikovurdering av senfølger av covid-19. Rundt 250 000 nye nordmenn er rammet av senfølger hvert år. Helseminister Vestre har videreført denne linjen, uten å ha evaluert konsekvensene med hensyn til senfølger, og har i stedet lagt skylden for det økte sykefraværet på at «pandemien har ført til at vi har litt annen atferd» (God morgen Norge, 17. september).\nSamtidig har regjeringens store kutt i FHIs budsjett i 2023, som førte til nedleggelsen av FHIs fagmiljø for inneklima, svekket Norges evne til å lage lover om tekniske krav til inneklima/byggverk som kan beskytte oss mot luftbårne virus som korona. Dette er et svik mot folkehelsa og en interessekonflikt for regjeringen – å anerkjenne senfølger som et samfunnsproblem ville rette oppmerksomheten mot «fri smitte»-politikken og de ressursene som regjeringen har fjernet.\nDersom økningen i sykefravær skyldes senfølger av covid-19, må dette tvinge regjeringen til å stå til ansvar for sin post-pandemiske håndtering og de påfølgende helsemessige og økonomiske konsekvensene.\nSå ja, årsaken spiller en stor rolle.\nRichard Aubrey White har ein doktorgrad i biostatistikk frå Harvard University. Han er forskar ved FHI, men uttalar seg ikkje på vegner av instituttet."
  },
  {
    "objectID": "post/2024-08-13-angrepet-mot-folkehelsa-fortsetter/angrepet-mot-folkehelsa-fortsetter.html",
    "href": "post/2024-08-13-angrepet-mot-folkehelsa-fortsetter/angrepet-mot-folkehelsa-fortsetter.html",
    "title": "Angrepet mot folkehelsa fortsetter",
    "section": "",
    "text": "Publisert i Fædrelandsvennen den 13. august 2024.\n\n\nRichard Aubrey White har doktorgrad i biostatistikk fra Harvard University og er forsker ved FHI, men uttaler seg ikke på vegne av arbeidsgiveren.\nPreben Aavitsland begynte sine angrep på bruk av munnbind den 30. januar 2020, hvor han kalte bruken «en kulturell greie.» Den 2. august i år fortsatte han i Fædrelandsvennen, ved å hevde at munnbind er en «lykkeamulett mot korona.» Selv om FHIs nye studie viser at munnbind reduserer luftveisinfeksjoner med 29 pst., er det ikke nok til å tilfredsstille Aavitsland om at de virker.\nFHI-studien har tre feil som undergraver Aavitslands argumenter.\nFor det første ble deltakerne bedt om å bruke munnbind i det offentlige rom i to uker, og så rapportere symptomene sine. Anta at perioden varte fra 14. til 27. februar: For en som har blitt smittet med covid-19 tar det mellom to og seks dager før man viser symptomer, som betyr at en person som ble smittet 13. februar trolig ikke vil vise symptomer før 18. februar (godt inne i studieperioden). Denne feilen påvirker den første halvdelen av studieperioden, noe som gjør at munnbind fremstår som mindre effektive enn de faktisk er. De fleste studiene ignorerer den første perioden for å unngå slike skjeve data, men ikke FHI-studien.\nDet blir som å utføre en graviditetstest den 28. februar for et par som har ubeskyttet sex hver dag fra 8. til 13. februar, og deretter blir bedt om å bruke kondom fra 14. til 27. februar. Da vil kondomer heller ikke virke særlig effektive.\nFor det andre ble ikke deltakerne bedt om å bruke munnbind på jobb. Munnbind, som kondomer og sikkerhetsbelter, er bare effektive mens de brukes.\nFor det tredje spres korona som røyk gjennom luften. Kirurgiske munnbind er ikke egnet for å beskytte mot luftbåren smitte, som er grunnen til at mange helsemyndigheter anbefaler FFP2-åndedrettsvern eller bedre.\nMed disse feilene er det overraskende at FHI fant at kirurgiske munnbind allikevel reduserte risikoen med 29 pst. Fjern den første uken med skjev data og be deltakerne bruke FFP2-åndedrettsvern (også på jobb), så vil man stå igjen med enda sterkere resultater. Noe en nylig gjennomgang konkluderte med.\nAavitsland nevner hudirritasjon og hodepine som ulempene ved munnbind, men ikke ulempene ved senfølger av covid-19, som kardiovaskulære komplikasjoner, kognitive problemer, hjernetåke og utmattelse. Senfølger er vanlige (men ignorert av norske helsemyndigheter); blant 20-64 åringene er legebesøk for utmattelse 75 pst. høyere i 2024 enn i 2019.\nDet er ironisk at Aavitsland frykter at munnbind vil oppmuntre syke mennesker til å gå på jobb og smitte andre. En av de beste metodene for å holde folk hjemme mens de er smittsomme, er å bruke hurtigtester for å identifisere riktig isolasjonsperiode (noen er smittsomme etter at symptomene har sluttet), noe han i VG har hevdet er unødvendig.\nHvorfor jobber Aavitsland så hardt for å undergrave folkehelsestrategier som er vanlige utenfor Norge? Er det fordi Norge har vært på villspor så lenge at det er vanskelig å snu uten å miste ansikt?"
  },
  {
    "objectID": "post/2023-08-26-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "href": "post/2023-08-26-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "title": "All-Cause Mortality in Norway",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2023-08-26-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n\n# Downloading data\nd_deaths &lt;- fread(\"https://data.ssb.no/api/v0/dataset/932937.csv?lang=en\")\nsetnames(d_deaths, c(\"sex\", \"age\", \"week\", \"content\", \"deaths_n\"))\nd_deaths[, isoweek := stringr::str_extract(week, \"[0-9][0-9]$\")]\nd_deaths[, isoyear := stringr::str_extract(week, \"^[0-9][0-9][0-9][0-9]\")]\nd_deaths[, isoyearweek := paste0(isoyear, \"-\", isoweek)]\nd_deaths[, isoweek := as.numeric(isoweek)]\nd_deaths[, isoyear := as.numeric(isoyear)]\nd_deaths[, week := NULL]\nd_deaths &lt;- d_deaths[isoyear &gt;= 2004]\nd_deaths &lt;- d_deaths[sex==\"0 Both sexes\"]\nd_deaths[, sex := NULL]\nd_deaths[, content := NULL]\nsetcolorder(d_deaths, c(\"age\", \"isoyear\", \"isoweek\", \"isoyearweek\", \"deaths_n\"))\nsetorder(d_deaths, age, isoyearweek)\n# Removing the latest 3 weeks of data (due to registration delay)\nmax_isoweek &lt;- d_deaths[isoyear == 2023 & !is.na(deaths_n)]$isoweek %&gt;%\n  max() - 3\nd_deaths &lt;- d_deaths[isoweek &lt;= max_isoweek]\n\n# recategorizing age\nunique(d_deaths$age)\nd_deaths[, age := fcase(\n  age == \"F00-04 0-4 years\", \"0-19\",\n  age == \"F05-09 5-9 years\", \"0-19\",\n  age == \"F10-14 10-14 years\", \"0-19\",\n age == \"F15-19 15-19 years\", \"0-19\",\n age == \"F20-24 20-24 years\", \"20-39\",\n age == \"F25-29 25-29 years\", \"20-39\",\n age == \"F30-34 30-34 years\", \"20-39\",\n age == \"F35-39 35-39 years\", \"20-39\",\n age == \"F40-44 40-44 years\", \"40-59\",\n age == \"F45-49 45-49 years\", \"40-59\",\n age == \"F50-54 50-54 years\", \"40-59\",\n age == \"F55-59 55-59 years\", \"40-59\",\n age == \"F60-64 60-64 years\", \"60-69\",\n age == \"F65-69 65-69 years\", \"60-69\",\n age == \"F70-74 70-74 years\", \"70-79\",\n age == \"F75-79 75-79 years\", \"70-79\",\n age == \"F80-84 80-84 years\", \"80-89\",\n age == \"F85-89 85-89 years\", \"80-89\",\n age == \"F90-94 90-94 years\", \"90+\",\n age == \"F95-99 95-99 years\", \"90+\",\n age == \"F100G5+ 100 years or older\", \"90+\"\n)]\nd_deaths &lt;- d_deaths[,.(\n  deaths_n = sum(deaths_n)\n), keyby=.(\n  age, isoyear, isoweek, isoyearweek\n)]\n\n\n# Aggregating\npd &lt;- d_deaths[, .(deaths_n = sum(deaths_n)), keyby = .(isoyear, age)]\npd[\n  csdata::nor_population_by_age_cats(list(\"0-19\"=0:19, \"20-39\"=20:39, \"40-59\"=40:59, \"60-69\"=60:69, \"70-79\"=70:79, \"80-89\"=80:89, \"90+\"=90:110))[granularity_geo==\"nation\"],\n  on = c(\"isoyear==calyear\", \"age\"),\n  pop_jan1_n := pop_jan1_n\n  ]\npd[, deaths_pr1000000 := 1000000*deaths_n/pop_jan1_n]\n\n# Estimating the baseline\nfor(x_age in unique(pd$age))for(isoyear_pred in 2011:2023){\n\n  # Determining the training data\n  if(isoyear_pred &lt;= 2019){\n    isoyear_train &lt;- (isoyear_pred-5):(isoyear_pred-1)\n  } else {\n    isoyear_train &lt;- 2010:2019\n  }\n  \n  # Fitting the model\n  fit &lt;- glm(\n    deaths_n ~ isoyear + offset(log(pop_jan1_n)), \n    #deaths_n ~ isoyear, \n    data = pd[age %in% x_age & isoyear %in% isoyear_train],\n    family = \"poisson\"\n  )\n  \n  # Predicting the baseline\n  pred &lt;- predict(\n      fit, \n      pd[age %in% x_age & isoyear %in% isoyear_pred]\n    ) %&gt;% \n    exp()\n  pd[\n    age %in% x_age & isoyear %in% isoyear_pred, \n    deaths_baseline_n := pred\n  ]\n}\n\n# Calculating the excess mortality\npd[, deaths_baseline_pr1000000 := 1000000*deaths_baseline_n/pop_jan1_n]\npd[, deaths_excess_n := deaths_n - deaths_baseline_n]\npd[, deaths_excess_pr100 := 100*deaths_excess_n/deaths_baseline_n]\n\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_pr1000000))\nq &lt;- q + annotate(\"rect\", xmin=2019.5, xmax=Inf, ymin=-Inf,ymax=Inf, fill=\"red\", alpha = 0.2)\nq &lt;- q + geom_line(mapping = aes(y=deaths_baseline_pr1000000, color = \"Baseline\"), lwd = 2, alpha = 0.8)\nq &lt;- q + geom_line(mapping=aes(color=\"Observed\"))\nq &lt;- q + geom_point(mapping=aes(color=\"Observed\"))\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2000, 2023, 2)\n  )\nq &lt;- q + scale_color_manual(NULL, values=c(\"green\", \"black\"))\nq &lt;- q + scale_y_continuous(\"Deaths per 1 000 000 population\")\nq &lt;- q + facet_wrap(~age, scales = \"free_y\")\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(caption = \"Data extracted 2023-08-29 from SSB table 932937.\")\nq &lt;- q + csstyle::set_x_axis_vertical()\nq\n\nWarning: Removed 7 rows containing missing values (`geom_line()`).\n\n\n\n\n\n\n\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_excess_pr100))\nq &lt;- q + annotate(\"rect\", xmin=2019.5, xmax=Inf, ymin=-Inf,ymax=Inf, fill=\"red\", alpha = 0.2)\nq &lt;- q + geom_col()\nq &lt;- q + geom_hline(yintercept = 0, color = \"black\")\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2011, 2023, 1)\n  )\nq &lt;- q + facet_wrap(~age)\nq &lt;- q + scale_y_continuous(\"Percentage excess (%)\")\n# q &lt;- q + scale_y_continuous(\n#   \"Number of excess deaths\",\n#   labels = csstyle::format_num_as_nor_num_0,\n#   breaks = seq(-1000, 4000, 500)\n# )\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Excess deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(\n  caption = \"Baseline calculated from a poisson regression of the previous 10 years of data.\\nBaselines for 2020, 2021, and 2022 calculated using data for 2010-2019.\\nData extracted 2023-08-29 from SSB table 932937.\"\n)\nq &lt;- q + csstyle::set_x_axis_vertical()\nq\n\nWarning: Removed 49 rows containing missing values (`position_stack()`)."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html",
    "title": "Sparse Inference",
    "section": "",
    "text": "Machine learning and statistical modeling are two important tools in data science that are used to make predictions and infer relationships between variables, respectively. Models for prediction aim to estimate the relationship between inputs and outputs in order to make accurate predictions about new, unseen data. In contrast, models for inference aim to understand the underlying relationships between variables in the data, often in the form of identifying causal relationships.\nIn this blog post, we will explore using models for inference using a simulated dataset, and we will apply penalized regression to perform feature selection on a binary outcome. Penalized regression is particularly useful in situations where the number of predictors (i.e. independent variables) is much larger than the sample size.\nWe will investigate the frequentist solution of using a two-stage solution with LASSO regression via glmnet and then using the selectiveInference package to perform post inference and adjust for the bias introduced by the selection process. We will also investigate a Bayesian solution that approximates a LASSO regression via a Laplace prior.\noptions(mc.cores = parallel::detectCores())\n\nfit &lt;- rstanarm::stan_glm(\n  formula = y ~ .,\n  data = data,\n  family = binomial(),\n  prior = rstanarm::laplace(),\n  chains = 4,\n  iter = 5000,\n  refresh=0\n)\n\nretval &lt;- data.frame(\n  var = names(coef(fit)),\n  Odds_Ratio = round(exp(coef(fit)),3),\n  round(exp(rstanarm::posterior_interval(fit, prob = 0.9)),3),\n  pvalue_equivalent = round(bayestestR::pd_to_p(bayestestR::p_direction(fit)$pd),2)\n)\nrow.names(retval) &lt;- NULL\nretval$var[retval$pvalue_equivalent &lt; 0.05] &lt;- paste0(\"*\", retval$var[retval$pvalue_equivalent &lt; 0.05])\nnames(retval) &lt;- c(\n  \"Variable\",\n  \"Odds ratio\",\n  \"Cred int 5%\",\n  \"Cred int 95%\",\n  \"Pvalue equivalent\"\n)\nretval\n\n      Variable Odds ratio Cred int 5% Cred int 95% Pvalue equivalent\n1  (Intercept)      1.009       0.951        1.070              0.80\n2          *x1      4.047       3.742        4.387              0.00\n3          *x2      2.969       2.768        3.186              0.00\n4          *x3      1.932       1.817        2.061              0.00\n5           x4      0.953       0.897        1.011              0.17\n6           x5      1.018       0.960        1.078              0.62\n7           x6      0.999       0.941        1.060              0.98\n8           x7      0.984       0.927        1.045              0.64\n9           x8      0.974       0.917        1.034              0.46\n10          x9      0.960       0.904        1.019              0.26\n11         x10      0.998       0.940        1.059              0.95\n12         x11      1.042       0.982        1.105              0.26\n13         x12      0.962       0.907        1.021              0.28\n14         x13      1.040       0.979        1.103              0.29\n15         x14      1.002       0.943        1.067              0.95\n16         x15      0.999       0.942        1.060              0.98\n17         x16      0.961       0.904        1.017              0.26\n18         x17      1.032       0.973        1.094              0.38\n19         x18      0.957       0.901        1.016              0.22\n20         x19      0.993       0.936        1.055              0.85\n21         x20      1.006       0.947        1.069              0.86\n22         x21      0.984       0.928        1.043              0.66\n23         x22      1.043       0.984        1.106              0.24\n24         x23      0.958       0.902        1.017              0.24\n25         x24      0.997       0.938        1.059              0.93\n26         x25      1.040       0.980        1.104              0.27\n27         x26      0.980       0.924        1.038              0.58\n28         x27      1.038       0.978        1.101              0.31\n29         x28      1.012       0.956        1.072              0.72\n30         x29      1.023       0.965        1.086              0.52\n31         x30      1.008       0.950        1.068              0.82\n32        *x31      0.903       0.851        0.960              0.00\n33         x32      1.025       0.969        1.087              0.47\n34         x33      1.032       0.971        1.096              0.38\n35         x34      1.002       0.944        1.062              0.97\n36         x35      1.007       0.951        1.066              0.84\n37         x36      1.049       0.989        1.110              0.18\n38         x37      1.023       0.964        1.085              0.51\n39         x38      1.060       0.999        1.125              0.11\n40         x39      1.021       0.963        1.084              0.56\n41         x40      1.030       0.971        1.092              0.43\n42         x41      0.985       0.927        1.045              0.68\n43         x42      1.005       0.947        1.068              0.89\n44         x43      1.025       0.966        1.089              0.50\n45         x44      0.947       0.891        1.003              0.12\n46         x45      1.044       0.984        1.108              0.24\n47         x46      1.012       0.953        1.072              0.74\n48         x47      1.006       0.948        1.065              0.88\n49         x48      0.953       0.900        1.012              0.20\n50         x49      0.960       0.906        1.019              0.27\n51         x50      0.968       0.913        1.028              0.39"
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#introduction",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#introduction",
    "title": "Sparse Inference",
    "section": "",
    "text": "Machine learning and statistical modeling are two important tools in data science that are used to make predictions and infer relationships between variables, respectively. Models for prediction aim to estimate the relationship between inputs and outputs in order to make accurate predictions about new, unseen data. In contrast, models for inference aim to understand the underlying relationships between variables in the data, often in the form of identifying causal relationships.\nIn this blog post, we will explore using models for inference using a simulated dataset, and we will apply penalized regression to perform feature selection on a binary outcome. Penalized regression is particularly useful in situations where the number of predictors (i.e. independent variables) is much larger than the sample size.\nWe will investigate the frequentist solution of using a two-stage solution with LASSO regression via glmnet and then using the selectiveInference package to perform post inference and adjust for the bias introduced by the selection process. We will also investigate a Bayesian solution that approximates a LASSO regression via a Laplace prior."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#simulating-a-dataset",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#simulating-a-dataset",
    "title": "Sparse Inference",
    "section": "Simulating a Dataset",
    "text": "Simulating a Dataset\nWe will simulate a dataset with n = 5000 people and p = 50 variables, where only three of the 50 variables will have an association with the binary outcome, and they will have odds ratios of 4, 3, and 2. The remaining variables will have no association with the outcome.\n\nlibrary(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nset.seed(123)\nn &lt;- 5000\np &lt;- 50\nx &lt;- matrix(rnorm(n * p), nrow = n)\nbeta &lt;- c(log(4), log(3), log(2), rep(0, 47))\nprob &lt;- plogis(x %*% beta)\ny &lt;- rbinom(n, 1, prob)\n\ndata &lt;- data.frame(cbind(y,x))\ncolnames(data) &lt;- c(\"y\", paste0(\"x\",1:ncol(x)))\n\nx &lt;- model.matrix(y ~ ., data = data)[,-1]\ny &lt;- data$y"
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#lasso-regression",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#lasso-regression",
    "title": "Sparse Inference",
    "section": "LASSO Regression",
    "text": "LASSO Regression\nWe will now fit a LASSO regression model using the glmnet package in R. LASSO is a popular method for feature selection in high-dimensional data, where the number of predictors p is much larger than the number of observations n.\n\n# get standard deviation of X, because we will need to standardize/scale it outside of glmnet\nsds &lt;- apply(x, 2, sd)\n\n# standardize x\nx_scaled &lt;- scale(x,TRUE,TRUE)\n\n# run glmnet\ncfit &lt;- glmnet::cv.glmnet(x_scaled,y,standardize=FALSE, family=\"binomial\")\ncoef(cfit)\n\n51 x 1 sparse Matrix of class \"dgCMatrix\"\n                     s1\n(Intercept) 0.008303975\nx1          1.081745656\nx2          0.821477348\nx3          0.452041341\nx4          .          \nx5          .          \nx6          .          \nx7          .          \nx8          .          \nx9          .          \nx10         .          \nx11         .          \nx12         .          \nx13         .          \nx14         .          \nx15         .          \nx16         .          \nx17         .          \nx18         .          \nx19         .          \nx20         .          \nx21         .          \nx22         .          \nx23         .          \nx24         .          \nx25         .          \nx26         .          \nx27         .          \nx28         .          \nx29         .          \nx30         .          \nx31         .          \nx32         .          \nx33         .          \nx34         .          \nx35         .          \nx36         .          \nx37         .          \nx38         .          \nx39         .          \nx40         .          \nx41         .          \nx42         .          \nx43         .          \nx44         .          \nx45         .          \nx46         .          \nx47         .          \nx48         .          \nx49         .          \nx50         ."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#no-confidence-intervals",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#no-confidence-intervals",
    "title": "Sparse Inference",
    "section": "No confidence intervals",
    "text": "No confidence intervals\nNote that LASSO regression does not provide any confidence intervals or p-values, only coeficient estimates."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#bayesian-logistic-regression-using-rstanarm",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#bayesian-logistic-regression-using-rstanarm",
    "title": "Sparse Inference",
    "section": "Bayesian Logistic Regression using rstanarm",
    "text": "Bayesian Logistic Regression using rstanarm\nAnother way to perform inference on a logistic regression model with feature selection is through Bayesian methods. In particular, we can use the rstanarm R package to fit a Bayesian logistic regression model with a Laplace prior."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#laplace-prior",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#laplace-prior",
    "title": "Sparse Inference",
    "section": "Laplace prior",
    "text": "Laplace prior\nThe Laplace prior is used to promote sparsity by assigning a probability distribution to the coefficients that puts more probability mass around zero. It is equivalent to LASSO regression (Tibshirani 1996)."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#p-value-equivalent",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#p-value-equivalent",
    "title": "Sparse Inference",
    "section": "P-value equivalent",
    "text": "P-value equivalent\nProbability of Direction (PoD) and p-values are both statistical measures used in hypothesis testing Makowski et al. (2019). They are similar in that they both provide evidence for or against a null hypothesis. PoD measures the proportion of posterior draws from a Bayesian model that are in the direction of the alternative hypothesis. It provides a measure of the strength of evidence for the alternative hypothesis relative to the null hypothesis. A high PoD value indicates strong evidence in favor of the alternative hypothesis, while a low PoD value indicates weak evidence in favor of the alternative hypothesis.\nSimilarly, a p-value measures the probability of obtaining a test statistic as extreme as or more extreme than the observed value, assuming that the null hypothesis is true. A low p-value indicates that the observed result is unlikely to have occurred by chance alone, providing evidence against the null hypothesis.\nTo convert PoD to a p-value equivalent, one approach is to use the following formula:\np-value = 2 * min(PoD, 1-PoD)\nThis formula assumes a two-tailed test and converts the PoD to a p-value for a test of the null hypothesis that the effect size is equal to zero. The resulting p-value can be interpreted as the probability of obtaining the observed result or a more extreme result under the null hypothesis."
  },
  {
    "objectID": "post/2023-04-14-sparse-inference/sparse-inference.html#conclusion",
    "href": "post/2023-04-14-sparse-inference/sparse-inference.html#conclusion",
    "title": "Sparse Inference",
    "section": "Conclusion",
    "text": "Conclusion\nThe blog article discusses the limitations of using LASSO (Least Absolute Shrinkage and Selection Operator) models for statistical inference, particularly in situations where the number of predictors (i.e. independent variables) is much larger than the sample size. In these cases, LASSO models can suffer from high variability in the estimated coefficients, which can lead to incorrect or unreliable conclusions.\nOne proposed solution to this problem is to use a two-stage inference approach, where LASSO is first used to select a subset of predictors, and then a separate statistical method (such as ordinary least squares) is used to estimate the coefficients for the selected predictors. However, this two-stage approach can also have limitations, such as a loss of power in the second stage and increased computational complexity.\nIn contrast, Bayesian statistics offer a one-stage inference approach that can provide more reliable and interpretable results in complex modeling situations. Bayesian statistics allow for the incorporation of prior knowledge and uncertainty in the model, which can help to reduce variability and improve accuracy. Bayesian methods also provide a framework for model comparison and selection, which can help to identify the most appropriate model for a given dataset.\nOverall, while LASSO models can be useful in certain situations, their limitations in high-dimensional data settings highlight the advantages of Bayesian statistics for reliable and interpretable statistical inference."
  },
  {
    "objectID": "post/2022-12-13-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "href": "post/2022-12-13-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "title": "All-Cause Mortality in Norway",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2022-12-13-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n\n# Downloading data\ndata &lt;- PxWebApiData::ApiData(\n  \"https://data.ssb.no/api/v0/en/table/07995\",\n  Kjonn = \"0\",\n  Alder = \"999A\",\n  Tid = as.character(2000:2022),\n  Uke = paste0(\"U\", formatC(1:52, width = 2, flag = \"0\"))\n)\n\n# Cleaning\nd_deaths &lt;- data$dataset[, c(\"Uke\", \"Tid\", \"value\")]\nsetDT(d_deaths)\nsetnames(d_deaths, c(\"week\", \"isoyear\", \"deaths_n\"))\nd_deaths[, isoweek := stringr::str_remove(week, \"U\")]\nd_deaths[, isoyearweek := paste0(isoyear, \"-\", isoweek)]\nd_deaths[, isoweek := as.numeric(isoweek)]\nd_deaths[, isoyear := as.numeric(isoyear)]\nd_deaths[, week := NULL]\nsetcolorder(d_deaths, c(\"isoyear\", \"isoweek\", \"isoyearweek\", \"deaths_n\"))\n\n# Removing the latest 3 weeks of data (due to registration delay)\nmax_isoweek &lt;- d_deaths[isoyear == 2022 & !is.na(deaths_n)]$isoweek %&gt;%\n  max() - 3\nd_deaths &lt;- d_deaths[isoweek &lt;= max_isoweek]\n\n\n# Aggregating\npd &lt;- d_deaths[, .(deaths_n = sum(deaths_n)), keyby = .(isoyear)]\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_n))\nq &lt;- q + geom_line()\nq &lt;- q + geom_point()\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2000, 2022, 2)\n  )\nq &lt;- q + scale_y_continuous(\n  \"Number of deaths\",\n  labels = csstyle::format_nor_num_0,\n  breaks = seq(33000, 38000, 1000)\n)\nq &lt;- q + expand_limits(y = c(33000, 38000))\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(caption = \"Data extracted 2022-12-13 from SSB table 07995.\")\nq\n\n\n\n\n\n\n\n\n\n# Estimating the baseline\nsetorder(d_deaths, isoyearweek)\nfor(isoyear_pred in 2011:2022) for(isoweek_model in unique(d_deaths$isoweek)){\n\n  # Determining the training data\n  if(isoyear_pred &lt;= 2019){\n    isoyear_train &lt;- (isoyear_pred-10):(isoyear_pred-1)\n  } else {\n    isoyear_train &lt;- 2010:2019\n  }\n  \n  # Fitting the model\n  fit &lt;- glm(\n    deaths_n ~ isoyear, \n    data = d_deaths[isoweek %in% isoweek_model & isoyear %in% isoyear_train],\n    family = \"poisson\"\n  )\n  \n  # Predicting the baseline\n  pred &lt;- predict(\n      fit, \n      d_deaths[isoweek %in% isoweek_model & isoyear %in% isoyear_pred]\n    ) %&gt;% \n    exp()\n  d_deaths[\n    isoweek %in% isoweek_model & isoyear %in% isoyear_pred, \n    deaths_baseline_n := pred\n  ]\n}\n\n\n# Calculating the excess mortality\nd_deaths[, deaths_excess_n := deaths_n - deaths_baseline_n]\n\n\n# Aggregating\npd &lt;- d_deaths[\n  !is.na(deaths_excess_n),\n  .(deaths_excess_n = sum(deaths_excess_n)), \n  keyby = .(isoyear)\n]\n\n# Plotting\nq &lt;- ggplot(pd, aes(x = isoyear, y = deaths_excess_n))\nq &lt;- q + geom_col()\nq &lt;- q + geom_hline(yintercept = 0, color = \"black\")\nq &lt;- q + scale_x_continuous(\n  \"Isoyear\",\n  breaks = seq(2011, 2022, 1)\n  )\nq &lt;- q + scale_y_continuous(\n  \"Number of excess deaths\",\n  labels = csstyle::format_nor_num_0,\n  breaks = seq(-1000, 4000, 500)\n)\nq &lt;- q + labs(\n    title = glue::glue(\n      \"Excess deaths in Norway, occurring between isoweeks 1 and {max_isoweek} (inclusive)\"\n    )\n  )\nq &lt;- q + labs(\n  caption = \"Weekly baseline calculated from a poisson regression of the previous 10 years of data.\\nBaselines for 2020, 2021, and 2022 calculated using data for 2010-2019.\\nData extracted 2022-12-13 from SSB table 07995.\"\n)\nq"
  },
  {
    "objectID": "post/2021-11-18-poster-prize-for-sykdomspulsen/poster-prize-for-sykdomspulsen.html",
    "href": "post/2021-11-18-poster-prize-for-sykdomspulsen/poster-prize-for-sykdomspulsen.html",
    "title": "Sykdomspulsen Receives Prize for Best Poster",
    "section": "",
    "text": "Sykdomspulsen’s poster “Sykdomspulsen - An exciting and forward-looking infrastructure and website for the real-time surveillance of Covid-19, other infections, and deaths” received the prize for “Best Poster” at Helse- og Kvalitetsregisterkonferansen 2021."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Richard Aubrey White",
    "section": "",
    "text": "Richard is an applied infectious diseases statistician based in Oslo, Norway. He is currently employed as the project manager for the Norwegian Syndromic Surveillance System (NorSySS), a surveillance system of infectious diseases based on consultations with general practitioners and out-of-hours primary care facilities, based in the Norwegian Institute of Public Health (Folkehelseinstituttet).\nHis international field experience includes performing needs assessments in Sri Lanka and developing/managing surveillance systems for Ebola in Sierra Leone, acute watery diarrhea/cholera in Mozambique, and maternal health in Palestine."
  },
  {
    "objectID": "index.html#contact",
    "href": "index.html#contact",
    "title": "Richard Aubrey White",
    "section": "Contact",
    "text": "Contact\nhello@rwhite.no"
  },
  {
    "objectID": "index.html#education-statistics",
    "href": "index.html#education-statistics",
    "title": "Richard Aubrey White",
    "section": "Education / Statistics",
    "text": "Education / Statistics\nHarvard University, USA\n2011–2012 / Ph.D. in Biostatistics\n2009–2011 / M.A. in Biostatistics (Frank Knox fellowship)\nUniversity of Wollongong, Australia\n2005–2009 / B. Advanced Mathematics in Applied Statistics (First Class Honours)"
  },
  {
    "objectID": "index.html#education-humanities",
    "href": "index.html#education-humanities",
    "title": "Richard Aubrey White",
    "section": "Education / Humanities",
    "text": "Education / Humanities\nUniversity of Bergen, Norway\n2022–2023 / One year program (Årsstudium) in Nordic languages and literature"
  },
  {
    "objectID": "blog.html",
    "href": "blog.html",
    "title": "Blog",
    "section": "",
    "text": "All-Cause Mortality in Norway\n\n\n\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB. \n\n\n\n\n\nMar 25, 2025\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nCovid er farligere enn du tror\n\n\n\n\n\nDet er stor grunn til å være bekymret for senskadene av covid. \n\n\n\n\n\nNov 11, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nSenfølger av covid-19 er vanlige og ofte vedvarende\n\n\n\n\n\nDet er ikke overraskende at økningen i sykefravær drives av diagnoser som alle er forbundet med senfølger etter koronasmitte. \n\n\n\n\n\nOct 2, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nLong Covid is Common and Often Permanent\n\n\n\n\n\nIt is not surprising that the increase in sick leave is driven by diagnoses that are all associated with long covid. \n\n\n\n\n\nOct 2, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nForebygg covid-19, forebygg sykefravær\n\n\n\n\n\nDet er gode bevis for at en stor del av økningen i sykefraværet skyldes senfølger av covid-19. \n\n\n\n\n\nSep 27, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nPrevent COVID-19, prevent sick leave\n\n\n\n\n\nThere is good evidence that a large proportion of the increase in sick leave is due to long covid. \n\n\n\n\n\nSep 27, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nAngrepet mot folkehelsa fortsetter\n\n\n\n\n\nPreben Aavitsland begynte sine angrep på bruk av munnbind den 30. januar 2020, hvor han kalte bruken «en kulturell greie.» \n\n\n\n\n\nAug 13, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nTendensiøs statistikk om senfølger\n\n\n\n\n\nMyndighetene må anerkjenne at senfølger eksisterer og utgjør et samfunnsproblem. \n\n\n\n\n\nMay 3, 2024\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nSlår alarm: Rekordmange til lege med utmattelse\n\n\n\n\n\nTallet på pasienter som oppsøker lege med utmattelse, har eksplodert under pandemien. Nå slår en FHI-forsker alarm. \n\n\n\n\n\nJan 4, 2024\n\n\n\n\n\n\n\n\n\n\n\n\nAll-Cause Mortality in Norway\n\n\n\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB. \n\n\n\n\n\nAug 26, 2023\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nMultivariate imputation by chained equations (MICE) with interaction terms\n\n\n\n\n\nExamining how MICE works with interaction terms. \n\n\n\n\n\nApr 20, 2023\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nSparse Inference\n\n\n\n\n\nExamining sparse inference using both frequentist and bayesian methodology. \n\n\n\n\n\nApr 14, 2023\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nSampling Bias\n\n\n\n\n\nExamining sampling bias in simulated data. \n\n\n\n\n\nFeb 23, 2023\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nAll-Cause Mortality in Norway\n\n\n\n\n\nExamining all-cause mortality in Norway using publically available mortality data from SSB. \n\n\n\n\n\nDec 13, 2022\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nCustom Airflow Docker Operator (Poor-Man’s Kubernetes)\n\n\n\n\n\nAirflow is a platform to programmatically author, schedule, and monitor workflows data. Operators are the main building blocks that encapsulate logic to do a unit of work. We have created a custom Airflow operator that 1) checks a remote YAML file and 2) then takes a decision to do one of two actions. This allows us to create a “poor-man’s Kubernetes”. \n\n\n\n\n\nJul 18, 2022\n\n\nRichard Aubrey White\n\n\n\n\n\n\n\n\n\n\n\n\nSykdomspulsen Receives Prize for Best Poster\n\n\n\n\n\nSykdomspulsen received the prize for best poster at Helse- og Kvalitetsregisterkonferansen 2021. \n\n\n\n\n\nNov 18, 2021\n\n\nRichard Aubrey White\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "CV",
    "section": "",
    "text": "hello@rwhite.no"
  },
  {
    "objectID": "cv.html#contact",
    "href": "cv.html#contact",
    "title": "CV",
    "section": "",
    "text": "hello@rwhite.no"
  },
  {
    "objectID": "cv.html#education-statistics",
    "href": "cv.html#education-statistics",
    "title": "CV",
    "section": "Education / Statistics",
    "text": "Education / Statistics\nHarvard University, USA\n2011–2012 / Ph.D. in Biostatistics\n2009–2011 / M.A. in Biostatistics (Frank Knox fellowship)\nUniversity of Wollongong, Australia\n2005–2009 / B. Advanced Mathematics in Applied Statistics (First Class Honours)"
  },
  {
    "objectID": "cv.html#education-humanities",
    "href": "cv.html#education-humanities",
    "title": "CV",
    "section": "Education / Humanities",
    "text": "Education / Humanities\nUniversity of Bergen, Norway\n2022–2023 / One year program (Årsstudium) in Nordic languages and literature"
  },
  {
    "objectID": "cv.html#skills",
    "href": "cv.html#skills",
    "title": "CV",
    "section": "Skills",
    "text": "Skills\n\nR (15+ years)\nSTATA (10+ years)\nDocker (5+ years)\nCI/CD (5+ years)\nPython (1 year)\nKubernetes (1 year)"
  },
  {
    "objectID": "cv.html#languages",
    "href": "cv.html#languages",
    "title": "CV",
    "section": "Languages",
    "text": "Languages\n\nEnglish (Fluent)\nNorwegian (B2)"
  },
  {
    "objectID": "cv.html#scientific-production",
    "href": "cv.html#scientific-production",
    "title": "CV",
    "section": "Scientific production",
    "text": "Scientific production\n\n89 scientific articles:\n\n64 866 citations\n45 h-index\n\n12 R packages as first author/maintainer:\n\nattrib (800 downloads/month from cran)\ncsalert (700 downloads/month from cran)\ncsdata (1000 downloads/month from cran)\ncsdb\ncsmaps (800 downloads/month from cran)\ncsstyle\ncstidy (700 downloads/month from cran)\ncsutil (700 downloads/month from cran)\norg (700 downloads/month from cran)\nplnr (800 downloads/month from cran)\nspread (10 downloads/month from cran)\ncs9\n\n3 R packages as co-author:\n\ncstime (900 downloads/month from cran)\nMOMO\nnowcast"
  },
  {
    "objectID": "cv.html#norwegian-institute-of-public-health-niphfhi",
    "href": "cv.html#norwegian-institute-of-public-health-niphfhi",
    "title": "CV",
    "section": "Norwegian Institute of Public Health (NIPH/FHI)",
    "text": "Norwegian Institute of Public Health (NIPH/FHI)\n\nProject Manager — Norwegian Syndromic Surveillance System (NorSySS)\n02.2023–now / Oslo, Norway\n\nProject manager for NorSySS, a surveillance system of infectious diseases based on consultations with general practitioners and out-of-hours primary care facilities. Complex statistical analyses are automatically run for all locations in Norway, producing reports and alerting various stakeholders.\nTechnology in use includes:\n\nKubernetes.\nDocker/Podman.\nCI/CD (Jenkins/GoCD/ArgoCD).\nApache Airflow.\nCore Surveillance 9 (cs9)\n\nSurveils 100+ syndromes.\nOrganized the 2023 Northern European Symposium on Automated Surveillance.\n\n\n\nTechnical Lead — Sykdomspulsen: Real-Time Surveillance\n07.2019–01.2023 / Oslo, Norway\n\nTech lead for Sykdomspulsen (8-person team), a real-time analysis and disease surveillance system. Complex statistical analyses were automatically run for all locations in Norway, producing reports and alerting various stakeholders.\nResponsible for training, mentoring, supervision, and quality assurance of statistical methods and code.\nTechnology in use included:\n\nKubernetes.\nDocker/Podman.\nCI/CD (Jenkins/GoCD/ArgoCD).\nApache Airflow.\nR/Python.\n\nSurveilled:\n\nAll cause/cause-specific/attributable mortality (part of the EuroMOMO network).\nVaccine associated mortality.\nCovid-19.\nInfluenza.\nTuberculosis.\nIPD.\nMeningococcal disease.\nPertussis.\nAntibiotic use and healthcare associated infection (NOIS-PIAH).\nGastritis.\n80+ syndromes via the Norwegian Syndromic Surveillance System (NorSySS).\n\nInteractive website for municipal health authorities (Sykdomspulsen for kommunehelsetjenesten).\nAPIs for internal/external use.\n1 000 000+ analyses per day.\n1 000+ automatic reports (pdf/excel/email/sms) per day.\n\n\n\nInfectious Diseases Statistician — Infectious Disease Epidemiology\n06.2014–06.2019 / Oslo, Norway\n\nAdvised outbreak teams and researchers in statistical concepts, methods, and programming.\nStatistical supervisor for five fellows of the European Programme for Intervention Epidemiology Training (EPIET) and nine PhD students:\n\nAnswered statistical questions.\nEnsured that the statistical methods chosen by them in their projects were correct.\nMentoring and supervising them in statistics.\nQuality assurance of statistical analyses in peer-reviewed publications.\n\nDeveloped statistical protocol for a 60 000-person longitudinal study regarding Norwegian water usage.\nModelled the 2014 Ebola outbreak to estimate the likelihood of a case flying to Norway and the subsequent usefulness of entry screening in Oslo airport.\nModelled the burden of HCV in Norwegian people who inject drugs.\nHead statistician on the data monitoring committee (DMC) for the:\n\nPEEP RCT in Haydom, Tanzania.\nSafer Births Moyo RCT in Muhimbili, Tanzania.\n\nDeveloped surveillance reports (and all relevant infrastructure and code for signal processing) in the format of interactive websites for:\n\nGastritis and upper-respiratory outbreaks using the Norwegian Syndromic Surveillance System (NorSySS).\nOutbreaks using the notifiable disease registry (MSIS).\nAll cause/cause-specific/attributable mortality (part of the EuroMOMO network).\n\n\n\n\nStatistician/Postdoc — Genes and Environment\n01.2012–05.2014 / Oslo, Norway\n\nDeveloped database management structures to allow for the construction of analysis datasets from multiple disparate sources (e.g. written questionnaires, lab toxicant concentrations, Illumina microbial data).\nInvestigated the relationship between seasonality, sunlight, and suicide.\nInvestigated the relationship between gun ownership and completed suicide in the US, highlighting the lack of method substitution where gun ownership is less prevalent."
  },
  {
    "objectID": "cv.html#consortium-for-statistics-in-disease-surveillance-csids",
    "href": "cv.html#consortium-for-statistics-in-disease-surveillance-csids",
    "title": "CV",
    "section": "Consortium for Statistics in Disease Surveillance (CSIDS)",
    "text": "Consortium for Statistics in Disease Surveillance (CSIDS)\n\nChairperson\n01.2023–now / Oslo, Norway\n\nOverseeing the collaboration between statisticians, epidemiologists, and researchers, working on the development of R packages used for disease surveillance."
  },
  {
    "objectID": "cv.html#norwegian-red-cross-norcross",
    "href": "cv.html#norwegian-red-cross-norcross",
    "title": "CV",
    "section": "Norwegian Red Cross (NorCross)",
    "text": "Norwegian Red Cross (NorCross)\n\nHead Statistician (IFRC)\n04.2024–05.2024 / Oslo, Norway\n\nHead statistician (remote) for a 1800-household multi-sector nationwide needs assessment, in response to the complex humanitarian emergency in Sri Lanka.\nDeveloped statistical protocol for all sectors, and analyzed most of the data\n\n\n\nHealth Officer (IFRC)\n08.2022–09.2022 / Colombo, Sri Lanka\n\nHead statistician for a 3100-household multi-sector nationwide needs assessment (annex), in response to the complex humanitarian emergency in Sri Lanka.\nDeveloped statistical protocol for all sectors, questions for the health sector, and analyzed most of the data.\n\n\n\nCommunity Based Surveillance Delegate (IFRC)\n04.2019–05.2019 / Beira, Mozambique\n\nResponded to a cholera outbreak.\nManaged a real-time surveillance system for people with diarrhea visiting Red Cross oral rehydration points as a part of the response to the cholera outbreak in Beira caused by Cyclone Idai.\nLiaised with the MOH on issues of interest, such as serious cases of diarrhea and self-reported bloody diarrhea."
  },
  {
    "objectID": "cv.html#norwegian-scientific-committee-for-food-and-environment-vkm",
    "href": "cv.html#norwegian-scientific-committee-for-food-and-environment-vkm",
    "title": "CV",
    "section": "Norwegian Scientific Committee for Food and Environment (VKM)",
    "text": "Norwegian Scientific Committee for Food and Environment (VKM)\n\nExternal Expert — Next Generation Risk Assessment in Practice\n01.2023–12/2023 / Oslo, Norway\n\nDeveloped statistical protocol for the evaluation of INVITES-IN, a tool for assessing the internal validity of in vitro studies."
  },
  {
    "objectID": "cv.html#palestinian-national-institute-of-public-health-pniph",
    "href": "cv.html#palestinian-national-institute-of-public-health-pniph",
    "title": "CV",
    "section": "Palestinian National Institute of Public Health (PNIPH)",
    "text": "Palestinian National Institute of Public Health (PNIPH)\n\nStatistician\n09.2017–09.2019 / Ramallah, Palestine\n\nTrained local staff in data management and statistical programming for the national maternal and child health registry.\nUsed raw survey data to validate indicators from the newly formed national healthcare worker registry."
  },
  {
    "objectID": "cv.html#world-health-organization-who",
    "href": "cv.html#world-health-organization-who",
    "title": "CV",
    "section": "World Health Organization (WHO)",
    "text": "World Health Organization (WHO)\n\nGIS Expert/Data Manager — Global Outbreak Alert and Response Network (GOARN)\n01.2015—02.2015 / Kambia, Sierra Leone\n\nResponded to the 2013–2016 Western African Ebola virus epidemic.\nDeveloped and managed a real-time surveillance system for the Ebola outbreak in Kambia, linking the national emergency number, Ebola holding centers, Ebola community care centers, Ebola treatment centers, and burials.\nGeocoded and mapped relevant outbreak data (alerts, cases, border crossings).\nGenerated daily sitreps using GIS data and epidemiological information from the surveillance database.\nTrained and supervised international and national staff in the use of the Kambian Ebola surveillance system.\n\n\n\nBiostatistician — Mortality and Burden of Disease\n04.2011–11.2011 / Geneva, Switzerland\n\nCollected cause of death data from multiple national cause of death registries into a database and calculated avoidable mortality estimates for disease groups over time, comparing trends in high income versus developing countries.\nProduced disease prevalence estimates for the Global Burden of Disease project (GBD 2010), most notably for vision loss, micronutrient deficiency, and stunting for all UN member nations, in all sex/age combinations, from 1990 to 2010.\n\n\n\nBiostatistician — Stop TB Department\n06.2010–11.2010 / Boston, USA\n\nLiaised with NGOs from South Africa, Uzbekistan, Bangladesh, and Peru to gain access to MDR-TB datasets, then managed, cleaned, and analysed the datasets.\nProvided recommendations for the WHO Guidelines for the Programmatic Management of Drug Resistant Tuberculosis (3rd edition) via multi-cohort survival analyses to determine factors affecting detection of MDR-TB and survival in a programmatic context."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html",
    "href": "mango-sticky-rice/mango-sticky-rice.html",
    "title": "Mango Sticky Rice",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n30min\n\n\nCooking time\n45min\n\n\nServes\nOne person"
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-i",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-i",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice (I)",
    "text": "Sticky rice (I)\n\nWash sticky (glutinous) rice until water runs clear.\nSoak sticky rice in water in fridge overnight."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-ii",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-ii",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice (II)",
    "text": "Sticky rice (II)\n\nDrain water.\nWrap in cheese cloth.\nSteam for 20 minutes."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-marinade",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-marinade",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice marinade",
    "text": "Sticky rice marinade\n\nMix all ingredients in saucepan and bring to a boil.\nRemove from heat."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-iii",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-iii",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice (III)",
    "text": "Sticky rice (III)\n\nRemove sticky rice from cheese cloth, place in bowl, add sticky rice marinade, and stir.\nCover for 20 minutes.\nStir again.\nPress/mold the sticky rice into a ball. Cover for 20 minutes."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-sauce",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-sauce",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice sauce",
    "text": "Sticky rice sauce\n\nMix all ingredients in saucepan and bring to a boil.\nStir until thickened."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-garnish",
    "href": "mango-sticky-rice/mango-sticky-rice.html#sticky-rice-garnish",
    "title": "Mango Sticky Rice",
    "section": "Sticky rice garnish",
    "text": "Sticky rice garnish\n\nToast sesame seeds in saucepan."
  },
  {
    "objectID": "mango-sticky-rice/mango-sticky-rice.html#serving",
    "href": "mango-sticky-rice/mango-sticky-rice.html#serving",
    "title": "Mango Sticky Rice",
    "section": "Serving",
    "text": "Serving\n\nPlate sticky rice and mango.\nPour sticky rice sauce on sticky rice.\nGarnish sticky rice with sesame seeds."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html",
    "href": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html",
    "title": "Custom Airflow Docker Operator (Poor-Man’s Kubernetes)",
    "section": "",
    "text": "This blog post has also been posted here."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#what-do-we-want",
    "href": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#what-do-we-want",
    "title": "Custom Airflow Docker Operator (Poor-Man’s Kubernetes)",
    "section": "What do we want?",
    "text": "What do we want?\nSykdomspulsen Analytics uses Airflow to schedule its tasks.\n\n\n\n\n\n\n\n\n\nAirflow and Sykdomspulsen Analytics’ tasks can be run on Kubernetes. This can be seen in the below graph, where one Airflow implementation dispatches tasks to both Server 1 and Server 2. However, with such a small team there is always the risk of something going wrong with a complicated Kubernetes setup. It is therefore preferable to have a failback solution that is independent of Kubernetes. We have achieved this by installing a duplicate Airflow system on each of the servers using Docker-compose. Each Docker-compose Airflow instance can dispatch tasks to its own server.\n\n\n\n\n\n\n\n\n\nHowever, this means that we have anywhere between 1 to 3 duplicate Airflow DAGs running at any time. All of these will be reading and writing to the same databases. This is obviously not desirable. We must have only one Airflow instance operative at any time."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#how-do-we-get-it",
    "href": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#how-do-we-get-it",
    "title": "Custom Airflow Docker Operator (Poor-Man’s Kubernetes)",
    "section": "How do we get it?",
    "text": "How do we get it?\nIt is not easy to seamlessly turn on and turn off multiple Airflow instances. We can, however, alter the operators inside each Airflow instance to be functional or non-functional.\nIt is for this reason that we developed a custom Airflow Docker operator. This custom Airflow Docker operator:\n\nChecks an external YAML config file (https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml) to see which server each DAG should be run on.\nChecks to see if this server is the correct one.\nIf this is not the correct server, change the command to be excecuted to: echo NOT CORRECT SERVER.\nExecutes the command inside the Docker container."
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#details",
    "href": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#details",
    "title": "Custom Airflow Docker Operator (Poor-Man’s Kubernetes)",
    "section": "Details",
    "text": "Details\nhttps://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml\n---\ndag_1: \"server-1.tld\"\ndocker-compose.yml (If using Podman)\n  volumes:\n    - /var/run/podman/podman.sock:/var/run/docker.sock\n  environment:\n    HOST_HOSTNAME: $HOSTNAME\n/opt/airflow/plugins/operators/sc_operators.py accesses the environmental variable HOST_HOSTNAME that is passed through from docker-compose.yml.\nimport os\nimport requests\nimport time\nimport yaml\n\nfrom airflow.operators.docker_operator import DockerOperator\n\nclass SCDockerOperator(DockerOperator):\n    def __init__(self, **kwargs) -&gt; None:\n        super().__init__(**kwargs)\n\n    def execute(self, context):\n        response = requests.get(\n            \"https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml\",\n            headers = {\"Cache-Control\": \"no-cache\"}\n        )\n        unparsed_data = response.text\n    \n        data = yaml.safe_load(unparsed_data)\n        \n        print(data)\n        print(self.dag.dag_id)\n        \n        if self.dag.dag_id not in data:\n            self.command = '''bash -c \"echo NOT CORRECT SERVER\"'''\n        elif data[self.dag.dag_id] != os.getenv(\"HOST_HOSTNAME\"):\n            self.command = '''bash -c \"echo NOT CORRECT SERVER\"'''\n        else:\n            print(\"OK\")\n        \n        time.sleep(5)\n        retval = super().execute(context)\n        return retval\n/opt/airflow/dags/dag_1.py\nimport random\nfrom operators.sc_operators import SCDockerOperator\n\ntask = SCDockerOperator(\n    task_id='my_task',\n    image='localhost/splanalytics:latest',\n    container_name= 'my_task_' + str(random.randint(10,100000)),\n    api_version='auto',\n    auto_remove=True,\n    command=cmd,\n    docker_url='unix://var/run/docker.sock',\n    network_mode='bridge',\n    privileged = True,\n    dag=dag\n)"
  },
  {
    "objectID": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#conclusion",
    "href": "post/2022-07-18-custom-airflow-docker-operator/custom-airflow-docker-operator.html#conclusion",
    "title": "Custom Airflow Docker Operator (Poor-Man’s Kubernetes)",
    "section": "Conclusion",
    "text": "Conclusion\nBy editing https://raw.githubusercontent.com/USERNAME/REPO/main/airflow-dag-on-server.yaml we can quickly choose which server will execute the desired task. This is an easy way to manually control identical installations of Airflow as a failback system."
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/sampling-bias.html",
    "href": "post/2023-02-23-sampling-bias/sampling-bias.html",
    "title": "Sampling Bias",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)"
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/sampling-bias.html#what-is-sampling-bias",
    "href": "post/2023-02-23-sampling-bias/sampling-bias.html#what-is-sampling-bias",
    "title": "Sampling Bias",
    "section": "What is Sampling Bias?",
    "text": "What is Sampling Bias?\nSampling bias refers to the phenomenon of a biased sample being used in a study that does not accurately represent the population being studied. This can happen in a number of ways, such as through selection bias, survivorship bias, or measurement bias. When sampling bias is present, it can lead to inaccurate results, incorrect estimates of associations between variables, and incorrect conclusions. This, in turn, can have an impact on public policy decisions, research funding, and clinical practice."
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/sampling-bias.html#types-of-sampling-bias",
    "href": "post/2023-02-23-sampling-bias/sampling-bias.html#types-of-sampling-bias",
    "title": "Sampling Bias",
    "section": "Types of Sampling Bias",
    "text": "Types of Sampling Bias\nThere are several types of sampling bias, including:\n\n1. Selection Bias\nSelection bias occurs when the selection of study participants is not random or representative of the larger population. This can happen when certain groups are excluded or overrepresented, leading to inaccurate conclusions about the study population.\nFor example, if a study only recruits participants from a single geographic region, the results may not be generalizable to the larger population. Similarly, if a study only recruits individuals with a certain health condition, the results may not accurately reflect the general population.\n\n\n2. Survivorship Bias\nSurvivorship bias occurs when only the surviving members of a population are included in a study. This can lead to inaccurate conclusions about the population, as those who did not survive may have had different characteristics or experiences.\nFor example, if a study only includes individuals who survived a specific disease, the results may not be generalizable to the larger population of individuals who did not survive.\n\n\n3. Measurement Bias\nMeasurement bias occurs when the measurement instruments or techniques used in a study are inaccurate or unreliable. This can result in inaccurate data and misinterpretation of results.\nFor example, if a study relies on self-reported data, individuals may underreport or overreport certain behaviors, leading to inaccurate conclusions about the study population. Similarly, if a study uses different measurement techniques for different groups, the results may not be comparable and may lead to inaccurate conclusions."
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/sampling-bias.html#example-of-sampling-bias-in-a-study",
    "href": "post/2023-02-23-sampling-bias/sampling-bias.html#example-of-sampling-bias-in-a-study",
    "title": "Sampling Bias",
    "section": "Example of Sampling Bias in a Study",
    "text": "Example of Sampling Bias in a Study\nTo better understand the impact of sampling bias on study results, let’s take a look at an example.\nSuppose we want to study the relationship between smoking and lung function. We know that in our city there are 100,000 people, 20,000 of whom are smokers. To our study we recruit 5,000 smokers and 5,000 non-smokers (oversampling the smokers, a type of selection bias). We also collect data on how frequently they exercise, whether they have good genes for lung function, and whether they frequently wear hats.\nWe now want to overcome our selection bias when assessing the association between the outcome of lung function and the exposures of exercise, good genes, and the frequency of hat wearing.\n\nset.seed(4)\n\nd &lt;- data.table(id = 1:100000)\nd[, is_smoker := rbinom(.N, 1, 0.2)]\nd[, probability_of_exercises_frequently := ifelse(is_smoker==T, 0.05, 0.3)]\nd[, exercises_frequently := rbinom(.N, 1, probability_of_exercises_frequently)]\nd[, has_good_genes := rbinom(.N, 1, 0.2)]\nd[, wears_hats_frequently := rbinom(.N, 1, 0.2)]\n\nd[, lung_function := 30 - 10 * is_smoker + 5 * exercises_frequently + 8 * has_good_genes + rnorm(.N, mean = 0, sd = 3)]\n\nd[, probability_of_selection_uniform := 1/.N]\n\nd[, probability_of_selection_oversample_smoker := ifelse(is_smoker==T, 5, 1)]\nd[, probability_of_selection_oversample_smoker := probability_of_selection_oversample_smoker/sum(probability_of_selection_oversample_smoker)]\n\n# We have a dataset with oversampled smokers\nd_oversampled_smokers &lt;- d[sample(1:.N, size = 5000, prob = probability_of_selection_oversample_smoker)]\n(weight_smoker &lt;- mean(d$is_smoker)/mean(d_oversampled_smokers$is_smoker))\n\n[1] 0.3700516\n\n(weight_non_smoker &lt;- mean(!d$is_smoker)/mean(!d_oversampled_smokers$is_smoker))\n\n[1] 1.747289\n\nd_oversampled_smokers[, weights := ifelse(is_smoker==T, weight_smoker, weight_non_smoker)]\n\n# The real associations:\n# is_smoker: -10 (also associated with exercises_frequently!)\n# exercises_frequently: +5 (also associated with is_smoker!)\n# has_good_genes: +8 (only associated with outcome, not with other exposures)\n# wears_hats_frequently: 0 (not associated with outcome nor other exposures)\nsummary(lm(lung_function ~ is_smoker + exercises_frequently + has_good_genes + wears_hats_frequently, data=d))\n\n\nCall:\nlm(formula = lung_function ~ is_smoker + exercises_frequently + \n    has_good_genes + wears_hats_frequently, data = d)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-12.6549  -2.0112   0.0055   2.0045  12.1835 \n\nCoefficients:\n                       Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)            30.02288    0.01421 2112.751   &lt;2e-16 ***\nis_smoker             -10.05071    0.02427 -414.150   &lt;2e-16 ***\nexercises_frequently    4.99532    0.02250  221.992   &lt;2e-16 ***\nhas_good_genes          7.98073    0.02355  338.831   &lt;2e-16 ***\nwears_hats_frequently  -0.01537    0.02360   -0.651    0.515    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 2.989 on 99995 degrees of freedom\nMultiple R-squared:  0.7975,    Adjusted R-squared:  0.7975 \nF-statistic: 9.847e+04 on 4 and 99995 DF,  p-value: &lt; 2.2e-16\n\n# When we run the model in the full data, excluding is_smoker, we get the following associations:\n# exercises_frequently: +7.2 (biased from association with is_smoker)\n# has_good_genes: +8 (not biased)\n# wears_hats_frequently: 0 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d)\n\nResiduals:\n    Min      1Q  Median      3Q     Max \n-21.056  -2.670   0.928   3.445  14.532 \n\nCoefficients:\n                       Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)           2.747e+01  2.109e-02 1302.327   &lt;2e-16 ***\nexercises_frequently  7.172e+00  3.605e-02  198.941   &lt;2e-16 ***\nhas_good_genes        7.958e+00  3.881e-02  205.044   &lt;2e-16 ***\nwears_hats_frequently 4.393e-04  3.888e-02    0.011    0.991    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 4.926 on 99996 degrees of freedom\nMultiple R-squared:  0.4502,    Adjusted R-squared:  0.4502 \nF-statistic: 2.73e+04 on 3 and 99996 DF,  p-value: &lt; 2.2e-16\n\n# When we run the model in the biased data, with oversampling of smokers (that has also an association with the outcome):\n# exercises_frequently: +9.8 (biased from association with is_smoker and the biased sampling)\n# has_good_genes: +7.6 (not biased)\n# wears_hats_frequently: +0.3 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d_oversampled_smokers)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-14.4131  -4.3613  -0.6571   4.4586  17.3734 \n\nCoefficients:\n                      Estimate Std. Error t value Pr(&gt;|t|)    \n(Intercept)            23.7436     0.1014 234.191   &lt;2e-16 ***\nexercises_frequently    9.8631     0.2140  46.095   &lt;2e-16 ***\nhas_good_genes          7.6164     0.1967  38.726   &lt;2e-16 ***\nwears_hats_frequently   0.3363     0.1905   1.765   0.0776 .  \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 5.501 on 4996 degrees of freedom\nMultiple R-squared:  0.4221,    Adjusted R-squared:  0.4218 \nF-statistic:  1217 on 3 and 4996 DF,  p-value: &lt; 2.2e-16\n\n# Run the model in the biased data, with weights:\n# exercises_frequently: +7.4 (biased from association with is_smoker)\n# has_good_genes: +7.6 (not biased)\n# wears_hats_frequently: +0.3 (not biased)\nsummary(lm(lung_function ~ exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers, weights = weights))\n\n\nCall:\nlm(formula = lung_function ~ exercises_frequently + has_good_genes + \n    wears_hats_frequently, data = d_oversampled_smokers, weights = weights)\n\nWeighted Residuals:\n    Min      1Q  Median      3Q     Max \n-12.537  -4.885  -2.767   2.077  18.233 \n\nCoefficients:\n                      Estimate Std. Error t value Pr(&gt;|t|)    \n(Intercept)           27.33919    0.09322 293.291   &lt;2e-16 ***\nexercises_frequently   7.40799    0.16055  46.140   &lt;2e-16 ***\nhas_good_genes         7.60104    0.17490  43.459   &lt;2e-16 ***\nwears_hats_frequently  0.26672    0.16734   1.594    0.111    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 4.859 on 4996 degrees of freedom\nMultiple R-squared:   0.45, Adjusted R-squared:  0.4497 \nF-statistic:  1363 on 3 and 4996 DF,  p-value: &lt; 2.2e-16\n\n# Run the model in the biased data, with is_smoker:\n# is_smoker: -9.9 (not biased)\n# exercises_frequently: +5.3 (not biased)\n# has_good_genes: +7.8 (not biased)\n# wears_hats_frequently: +0.2 (not biased)\nsummary(lm(lung_function ~ is_smoker + exercises_frequently + has_good_genes + wears_hats_frequently, data=d_oversampled_smokers))\n\n\nCall:\nlm(formula = lung_function ~ is_smoker + exercises_frequently + \n    has_good_genes + wears_hats_frequently, data = d_oversampled_smokers)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-10.6202  -1.9903  -0.0699   1.9855  11.1052 \n\nCoefficients:\n                      Estimate Std. Error  t value Pr(&gt;|t|)    \n(Intercept)           29.83110    0.07786  383.149   &lt;2e-16 ***\nis_smoker             -9.88043    0.08978 -110.051   &lt;2e-16 ***\nexercises_frequently   5.25052    0.12300   42.688   &lt;2e-16 ***\nhas_good_genes         7.79706    0.10630   73.350   &lt;2e-16 ***\nwears_hats_frequently  0.15569    0.10296    1.512    0.131    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 2.973 on 4995 degrees of freedom\nMultiple R-squared:  0.8313,    Adjusted R-squared:  0.8311 \nF-statistic:  6152 on 4 and 4995 DF,  p-value: &lt; 2.2e-16"
  },
  {
    "objectID": "post/2023-02-23-sampling-bias/sampling-bias.html#conclusion",
    "href": "post/2023-02-23-sampling-bias/sampling-bias.html#conclusion",
    "title": "Sampling Bias",
    "section": "Conclusion",
    "text": "Conclusion\nConclusion: Biased datasets can be corrected for by either:\n\nSample weights\nIncluding the sampling variables as covariates in the regression model"
  },
  {
    "objectID": "post/2023-04-20-mice-with-interaction-terms/mice-with-interaction-terms.html",
    "href": "post/2023-04-20-mice-with-interaction-terms/mice-with-interaction-terms.html",
    "title": "Multivariate imputation by chained equations (MICE) with interaction terms",
    "section": "",
    "text": "We simulate a dataset where it is not harmful to be male nor a smoker (coefficient = 0), but the interaction of the two is very harmful (coefficient = 5).\nWe then set the outcome to missing for 70% of the males and 70% of the smokers, and run the following analyses:\n\nComplete case analysis\nBlindly imputed analysis (using MICE)\nImputed analysis (using MICE) where males and females were imputed separately.\n\nWe repeat this for multiple datasets with various sample sizes, to see how the imputation strategies are affected by the size of the dataset.\n\nlibrary(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nsim_function &lt;- function(data, argset){\n  data &lt;- data.table(id = 1:argset$n)\n  \n  data[, is_male := rbinom(.N, 1, 0.5)]\n  data[, is_smoker := rbinom(.N, 1, 0.5)]\n  data[, lung_function := -1 + 0 * is_male + 0 * is_smoker + 5 * is_male * is_smoker + rnorm(.N, sd = 2)]\n  \n  data_missing &lt;- copy(data)\n  data_missing[is_male==1 & runif(.N)&lt;0.7, lung_function := NA]\n  data_missing[is_smoker==1 & runif(.N)&lt;0.7, lung_function := NA]\n  \n  # complete case analysis\n  coef_complete_case &lt;- coef(summary(lm(lung_function ~ is_male*is_smoker, data = data_missing)))[,1]\n  \n  # we impute the data blindly\n  data_imputed &lt;- mice::mice(data_missing, print=F, m = 20)\n  fit_imputed &lt;- with(data_imputed, lm(lung_function ~ is_male*is_smoker))\n  coef_imputed_blindly &lt;- mice::pool(fit_imputed)$pooled$estimate\n  \n  # we impute the data separately for males and females\n  data_imputed_male &lt;- mice::mice(data_missing[is_male==1], print=F, m = 20)\n  data_imputed_female &lt;- mice::mice(data_missing[is_male==0], print=F, m = 20)\n  data_imputed_sex_specific &lt;- mice:::rbind.mids(data_imputed_male, data_imputed_female)\n  fit_imputed &lt;- with(data_imputed_sex_specific, lm(lung_function ~ is_male*is_smoker))\n  coef_imputed_separately &lt;- mice::pool(fit_imputed)$pooled$estimate\n  \n  retval &lt;- data.table(\n    var = names(coef_complete_case),\n    coef_complete_case,\n    coef_imputed_blindly,\n    coef_imputed_separately,\n    n = argset$n\n  )\n  return(retval)\n}\n\np &lt;- plnr::Plan$new()\nfor(n in c(100, 500, 1000, 2000, 4000)) for(i in 1:100){\n  p$add_argset(\n    name = uuid::UUIDgenerate(),\n    n=n,\n    i=i\n  )\n}\np$apply_action_fn_to_all_argsets(sim_function)\nset.seed(1234)\nresults &lt;- p$run_all()\nresults &lt;- rbindlist(results)\n\nresults[var == \"is_male:is_smoker\", .(\n  coef_complete_case = round(mean(coef_complete_case), 2),\n  coef_imputed_blindly = round(mean(coef_imputed_blindly), 2),\n  coef_imputed_separately = round(mean(coef_imputed_separately), 2)\n), keyby=.(n)] %&gt;% \n  print()\n\n      n coef_complete_case coef_imputed_blindly coef_imputed_separately\n1:  100               5.06                 1.33                    2.60\n2:  500               4.97                 3.56                    4.89\n3: 1000               5.10                 4.49                    5.12\n4: 2000               5.03                 4.97                    5.09\n5: 4000               5.05                 5.09                    5.09\n\n\nWe can see that (in this simple example) complete case analysis correctly captured the interaction’s coefficient of 5.\nMore interesting is that with lower sample sizes, imputing males/females separately performed better than imputing blindly, however, once the sample size became sufficient then there was little difference between the two methods.\nThe code used to impute the data separately for males and females:\ndata_imputed_male &lt;- mice::mice(data_missing[is_male==1], print=F, m = 20)\ndata_imputed_female &lt;- mice::mice(data_missing[is_male==0], print=F, m = 20)\ndata_imputed_sex_specific &lt;- mice:::rbind.mids(data_imputed_male, data_imputed_female)"
  },
  {
    "objectID": "post/2024-05-03-tendensios-statistikk-om-senfolger/tendensios-statistikk-om-senfolger.html",
    "href": "post/2024-05-03-tendensios-statistikk-om-senfolger/tendensios-statistikk-om-senfolger.html",
    "title": "Tendensiøs statistikk om senfølger",
    "section": "",
    "text": "Publisert i Dag og Tid den 3. mai 2024.\n\n\nI innlegget «Meir om seinfølger» i Dag og Tid 26. april hevder Preben Aavitsland ved Folkehelseinstituttet at dødeligheten blant unge har vært stabil siden 2015, og trekker en rekke studier om senfølger av covid-19 i tvil. Mens han er opptatt med å kritisere andres omgang med fakta, er Aavitslands bruk av statistikk også tvilsom.\nAavitsland, en av medforfatterne til FHIs overdødelighetsrapport (16. april 2024), skriver at rapporten viser at dødsfall blant personer under 40 har vært stabile siden 2015, men i rapporten står det at det var en overdødelighet på 105 personer under 40 i 2023. Videre er påstanden om en «stabil trend» fra 2015 til 2019 feilaktig.\nTrenden fra 2000 til 2019 avslører at Aavitslands «stabile trend» er normal variasjon innenfor en 20-årig konstant nedgang, brått avsluttet av et oppsving i 2023. Rapporten viser kun data fra 2010, noe som legger kunstig vekt på tilfeldig variasjon i senere år. Disse nyansene er nødvendige for å forstå totalbildet, men Aavitslands ønske er tydeligvis ikke å vise helheten.\nAavitsland hevder at FHI-rapporten viser at det ikke er økning i hjerte- og kardødsfall hos yngre. Det kan stemme, men man kan ikke bruke denne rapporten til å fastslå dette. Rapporten viser data per kvartal, som påvirkes av sesongmessige variasjoner, og viser kun tall f.o.m. 2016, uten en langsiktig trendanalyse.\nAavitsland viser til en systematisk gjennomgang publisert i BMC Medicine, et tidsskrift med begrenset anerkjennelse, og hevder at «tilsynelatende urovekkende funn skyldes skjevheter i studiene». Konklusjonen i samme artikkel sier noe helt annet: «Det er et bredt spektrum av langvarige hjertekomplikasjoner av covid-19.»\nAavitsland påstår ofte at studier som viser at senfølger er både vanlige og alvorlige, er skjeve og uten verdi for Norge. Statistiske teknikker kan måle hvor motstandsdyktige funn er mot umålte skjevheter. Jeg har brukt dem og funnet at mange av studiene som Aavitsland har avskrevet, faktisk er robuste. Det er uklart hvorfor de ignoreres av Aavitsland. Vurdering av metodisk validitet bør overlates til erfarne statistikere.\nAavitsland nevner at FHI gjør systematiske litteraturgjennomganger om senfølger, og viser til en selvpublisert rapport fra 2022 som ikke er fagfellevurdert. Hva med 2023 og 2024?\nI juli 2023 publiserte FHI en til, som vurderte 6918 studier, men regnet alle som ikke relevante. De ble sittende igjen med null studier. Dette er ikke et unntak. Aavitsland avviser ofte fagfellevurderte artikler i de mest anerkjente tidsskriftene i verden som viser at covid-19 har alvorlige langtidskonsekvenser for mange, selv etter vaksinasjon.\nEn nylig studie av 188.137 nordmenn viste en sammenheng mellom covid-19 og langsiktige hukommelsesproblemer og ble publisert i det verdenskjente tidsskriftet NEJM. Allikevel har den ikke påvirket norsk helsepolitikk. Verken regjeringens koronastrategi eller FHIs risikovurderinger nevner senfølger. Er dette fordi eksistensen av senfølger går imot den nåværende strategien, hvor vi motsetter oss smitteverntiltak?\nAavitsland fremstiller det som om vi kun har to muligheter: ukontrollert smitte eller nedstengning. I Dag og Tid 15. mars ga FHIs Carol Holm-Hansen flere alternativ som kan beskytte oss uten å være inngripende. Men før vi snakker om løsningen, må myndighetene først anerkjenne at senfølger eksisterer og utgjør et samfunnsproblem.\nBør vi klandre regjeringen, FHI eller begge to? Uansett er det den norske befolkningen som betaler prisen. Med helsa som innsats. For lesere som ikke kjenner noen som er påvirket av senfølger, gi det noen covid-bølger til. WHO anslår at 1 av 10 infeksjoner gir senfølger, og studier anslår at vaksiner kun er ca. 50 prosent effektive i å forebygge dem.\nNorge har hatt 5 millioner infeksjoner i året siden 2022. Denne gangen vil jeg la leseren gjøre statistikken selv.\nRichard Aubrey White har ein doktorgrad i biostatistikk frå Harvard University. Han er forskar ved FHI, men uttalar seg ikkje på vegner av instituttet."
  },
  {
    "objectID": "post/2024-01-04-rekordmange-til-lege-med-utmattelse/rekordmange-til-lege-med-utmattelse.html",
    "href": "post/2024-01-04-rekordmange-til-lege-med-utmattelse/rekordmange-til-lege-med-utmattelse.html",
    "title": "Slår alarm: Rekordmange til lege med utmattelse",
    "section": "",
    "text": "Publisert på nrk.no den 4. jan 2024.\nSaken oppsummert:\n\nDet har vært en dramatisk økning i antall pasienter som oppsøker lege for utmattelse under pandemien.\nØkningen har skjedd i alle aldersgrupper, med unntak av barn i alderen 0–4 år.\nFHI-statistiker Richard Aubrey White og andre forskere er bekymret for utviklingen.\nØkningen i utmattelse kom samtidig med omikronvarianten, og det er en tidsmessig sammenheng mellom smittebølger og økning i utmattelse.\nFlere store studier viser at covid-19 kan gi alvorlige senfølger.\nForsker og infeksjonsmedisiner Arne Søraas oppfordrer norske folkehelsemyndigheter til å oppdatere seg på internasjonal forskning på området.\nFagdirektør Preben Aavitsland i FHI mener det ikke er nok god kunnskap til å slå fast at covid-19 fører til alvorlige senfølger."
  },
  {
    "objectID": "post/2024-10-02-senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende/senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende.html",
    "href": "post/2024-10-02-senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende/senfolger-av-covid-19-er-vanlige-og-ofte-vedvarende.html",
    "title": "Senfølger av covid-19 er vanlige og ofte vedvarende",
    "section": "",
    "text": "Publisert i Aftenposten den 2. oktober 2024.\n\n\nI en artikkel i Aftenposten 27. september hevder professor og direktør Preben Aavitsland ved Folkehelseinstituttet (FHI) at senfølger av covid-19 er «sjeldne og går ofte over etter hvert».\nDette er feil — senfølger av covid-19 er vanlige og ofte vedvarende.\nAavitslands påstand om varigheten kommer trolig fra FHIs studie, som kun analyserer antall fastlegebesøk etter koronasmitte. Hans tolkning av at færre besøk betyr at senfølgene har gått over, er feilaktig. Folk slutter å gå til legen når legen ikke kan hjelpe dem, selv om senfølgene vedvarer.\nØker den samlede risikoen\nKoronastudien, som ser på helse i stedet for fastlegebesøk, viste nylig at covid-19 førte til 6 prosent risiko for hukommelsesproblemer mer enn ett år senere hos nordmenn uten immunitet. Vaksiner og immunitet er cirka 50 prosent effektive mot senfølger, så risikoen kan reduseres til 3 prosent for de fleste. Dette gjelder pr. infeksjon.\nDen samlede risikoen etter to infeksjoner er da 5,9 prosent, etter fire infeksjoner 11,5 prosent, etter seks infeksjoner 16,7 prosent.\nDette er ett eksempel, men flere studier viser det samme resultatet — gjentatte infeksjoner øker den samlede risikoen til et uakseptabelt nivå. Dette må ses i konteksten av dagens «fri smitte»-strategi, der folk i gjennomsnitt blir smittet én gang i året.\nDet er ikke overraskende at økningen i sykefravær er drevet av tre diagnosekoder (A04, P02 og P29), som alle er forbundet med senfølger.\nBagatelliserer byrden\n«Fri smitte»-strategien var støttet av FHIs risikovurdering, som kun så på akutt covid-19. FHI har aldri publisert en risikovurdering av strategien som nevner senfølger.\nI lys av det høye sykefraværet, trolig på grunn av senfølger, har de som var ansvarlige for strategien og de manglende risikovurderingene, gode insentiver til å bagatellisere byrden senfølger utgjør for samfunnet.\nVi må forebygge covid-19-smitte og senfølger. Dette kan vi gjøre ved å forbedre ventilasjonen, bruke luftrensere og anbefale bruk av FFP2-åndedrettsvern når smitten er høy.\nRichard Aubrey White har en doktorgrad i biostatistikk fra Harvard University. White er forsker ved Folkehelseinstituttet, men uttaler seg ikke på vegne av FHI."
  },
  {
    "objectID": "post/2024-09-27-prevent-covid-19-prevent-sick-leave/prevent-covid-19-prevent-sick-leave.html",
    "href": "post/2024-09-27-prevent-covid-19-prevent-sick-leave/prevent-covid-19-prevent-sick-leave.html",
    "title": "Prevent COVID-19, prevent sick leave",
    "section": "",
    "text": "Published in Dag of Tid the 27th of September 2024.\n\n\nThis is a translation of the original Norwegian op-ed, and discrepancies may exist.\nIn the article “Not a Question of Morality, but of Good Treatment” in Dag og Tid on September 20, Marit Hermansen, Chief Medical Officer at NAV, claims that “the cause of mild mental health issues doesn’t play a large role. Whether the cause is COVID-19 or something else, many will benefit health-wise from being in adapted activity and work.”\nThis is incorrect.\nA bit of background: Sick leave has increased in several diagnostic codes compared to 2019. NAV’s sick leave registry has no code for Long COVID, meaning that people with Long COVID are spread across several codes based on symptoms. Long COVID can affect nearly all organ systems, including the brain. The largest increases are in the codes A04 (fatigue), P02 (acute stress reaction), and P29 (psychological symptom/complaint other). Fatigue is clearly linked to Long COVID, yet the narrative focuses only on “mild mental health issues” (P02 and P29). NAV researchers Moberg and Kabashi found that sick leave due to acute COVID-19 was associated with 25% and 18% higher sick leave for P02 and P29, respectively, in the following 12 weeks.\nAccording to the WHO, 1 in 10 COVID-19 infections lead to Long COVID, and studies estimate that vaccines are only about 50 % effective in preventing it. With the current “mass infection” strategy, Norway has had 5 million COVID-19 infections every year since 2022. Based on this, we can expect around 250,000 new cases of Long COVID each year — including in 2024 and 2025. The German Health Minister, Professor Lauterbach stated on September 17, 2024: “Long COVID is not gone, and it will not disappear. There is often no cure for those affected — and the number of those affected is growing.”\nThere is strong evidence that a large part of the increase in sick leave is due to Long COVID.\nNow, to Hermansen’s point: Good treatment must be adapted to the cause of the illness. If a person is burned out due to life or work circumstances, activity can help. But if someone is misdiagnosed as burned out, when they are actually suffering from Long COVID, then activity without adequate consideration of post-exertional malaise (PEM) can potentially be harmful.\nWe should prevent illness, not just treatment. If the increase in sick leave is due to Long COVID, then we must prevent COVID-19. This can be done by improving ventilation, using air purifiers, and recommending the use of FFP2 respirators in public spaces when there is high transmission. These protective measures are effective and do not significantly affect daily life. We can reduce the problem itself, and people can avoid getting sick — what we lack is the will to do so.\nIn the end, it’s about culpability. Since 2022, the country, under the Labour Party and Centre Party government, has pursed a “mass infection” strategy, without a risk assessment of Long COVID. Around 250,000 new Norwegians are affected by Long COVID every year. Health Minister Vestre has continued this policy, without evaluating the consequences regarding Long COVID, and has instead blamed the increased sick leave on “the pandemic [causing] us to behave a little differently” (Good Morning Norway, September 17).\nAt the same time, the government’s significant cuts to the Norwegian Insitute of Public Health’s budget in 2023, which led to the closure of the center for indoor air quality, have weakened Norway’s ability to legislate technical requirements for indoor air quality that can protect us against airborne viruses like SARS-CoV-2 (the virus that causes COVID-19). This is a betrayal of public health and a conflict of interest for the government — acknowledging Long COVID as a societal problem would draw attention to the “mass infection” strategy and the resources the government has removed.\nIf the increase in sick leave is due to Long COVID, then the government must be forced to take responsibility for its post-pandemic management and the subsequent health and economic consequences.\nSo yes, the cause does play a large role.\nRichard Aubrey White holds a PhD in biostatistics from Harvard University. He is a researcher at the Norwegian Institute of Public Health, but does not speak on behalf of the institute."
  },
  {
    "objectID": "post/2025-03-25-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "href": "post/2025-03-25-all-cause-mortality-in-norway/all-cause-mortality-in-norway.html",
    "title": "All-Cause Mortality in Norway",
    "section": "",
    "text": "library(data.table)\nlibrary(magrittr)\nlibrary(ggplot2)\n\nif (interactive()) {\n  folder_location &lt;- \"post/2025-03-25-all-cause-mortality-in-norway/\"\n} else {\n  folder_location &lt;- \"\"\n}\n\n\n# Downloading data\n\ndata &lt;- PxWebApiData::ApiData(\n  \"https://data.ssb.no/api/v0/en/table/07995\",\n  Kjonn = \"0\",\n  Alder = \"999A\",\n  Tid = as.character(2010:2024),\n  Uke = paste0(\"U\", formatC(1:52, width = 2, flag = \"0\"))\n)\n\n# Cleaning\nd_deaths &lt;- data$dataset[, c(\"Uke\", \"Tid\", \"value\")]\nsetDT(d_deaths)\nsetnames(d_deaths, c(\"week\", \"isoyear\", \"deaths_n\"))\nd_deaths[, isoweek := stringr::str_remove(week, \"U\")]\nd_deaths[, isoyearweek := paste0(isoyear, \"-\", isoweek)]\nd_deaths[, isoweek := as.numeric(isoweek)]\nd_deaths[, isoyear := as.numeric(isoyear)]\nd_deaths[, week := NULL]\nsetcolorder(d_deaths, c(\"isoyear\", \"isoweek\", \"isoyearweek\", \"deaths_n\"))\n\n\n# Loading the cleaned data\nd_deaths &lt;- readxl::read_excel(glue::glue(\"{folder_location}10325_20250325-102517.xlsx\"))\nsetDT(d_deaths)\nd &lt;- melt.data.table(\n  d_deaths, \n  id.vars = \"age\",\n  variable.factor = FALSE,\n  value.name = \"deaths_n\"\n  )\nd[, year := as.numeric(variable)]\nd[, variable := NULL]\nd[, age_numeric := stringr::str_extract(age, \"\\\\d+\") %&gt;% as.numeric()]\nd[, age_cat := fcase(\n  age_numeric == 0, \"000_000\",\n  age_numeric %in% 1:19, \"001_019\",\n  age_numeric %in% 20:39, \"020_039\",\n  age_numeric %in% 40:64, \"040_064\",\n  age_numeric %in% 65:79, \"065_079\",\n  age_numeric %in% 80:200, \"080p\"\n)]\nd &lt;- d[, .(\n  deaths_n = sum(deaths_n)\n), keyby = .(year, age_cat)]\n\n\np &lt;- csdata::nor_population_by_age_cats(cats = list(\n  \"000_000\" = 0,\n  \"001_019\" = 1:19,\n  \"020_039\" = 20:39,\n  \"040_064\" = 40:64,\n  \"065_079\" = 65:79,\n  \"080p\" = 80:200\n))[location_code==\"nation_nor\"]\n\nd[p, on = c(\"year==calyear\", \"age_cat==age\"), pop_jan1_n := pop_jan1_n]\nd[,deaths_vs_pop_pr100000 := 100000*deaths_n/pop_jan1_n]\n\nd[, year_frozen_at_2023 := year]\nd[year &gt;= 2023, year_frozen_at_2023 := 2023]\n\n\np &lt;- plnr::Plan$new()\np$add_data(name=\"data\", direct = d)\n\np$add_argset(age = \"000_000\")\np$add_argset(age = \"001_019\")\np$add_argset(age = \"020_039\")\np$add_argset(age = \"040_064\")\np$add_argset(age = \"065_079\")\np$add_argset(age = \"080p\")\n\nanalysis_1 &lt;- function(argset, data){\n  if(plnr::is_run_directly()){\n    data &lt;- p$get_data()\n    argset &lt;- p$get_argset(1)\n  }\n  pd &lt;- data$data[age_cat==argset$age & year&gt;=2010]\n\n  # fit &lt;- rstanarm::stan_glm(N ~ splines::ns(isoyear_frozen_at_2023, df = 2), data = pd[isoyear&lt;=2019], offset=log(pop_jan1_n), family = poisson)\n  fit &lt;- rstanarm::stan_glm(deaths_n ~ year_frozen_at_2023, data = pd[year&lt;=2019], offset=log(pop_jan1_n), family = poisson)\n\n  pred &lt;- rstanarm::posterior_predict(fit, pd, offset=log(pd$pop_jan1_n))\n  retval &lt;- apply(pred, 2, quantile, probs = c(0.05, 0.5, 0.95)) %&gt;%\n    t() %&gt;%\n    as.data.frame()\n  names(retval) &lt;- c(\"p5\", \"p50\", \"p95\")\n\n  return(cbind(pd, retval))\n}\n\np$apply_action_fn_to_all_argsets(fn = analysis_1)\n\nraw &lt;- p$run_all()\n\n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 3e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.3 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.023 seconds (Warm-up)\nChain 1:                0.026 seconds (Sampling)\nChain 1:                0.049 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 7e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.024 seconds (Warm-up)\nChain 2:                0.028 seconds (Sampling)\nChain 2:                0.052 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 7e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.022 seconds (Warm-up)\nChain 3:                0.025 seconds (Sampling)\nChain 3:                0.047 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 9e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.09 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.024 seconds (Warm-up)\nChain 4:                0.027 seconds (Sampling)\nChain 4:                0.051 seconds (Total)\nChain 4: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 1.3e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.13 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.023 seconds (Warm-up)\nChain 1:                0.025 seconds (Sampling)\nChain 1:                0.048 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 8e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 2:                0.029 seconds (Sampling)\nChain 2:                0.054 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 9e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.09 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 3:                0.031 seconds (Sampling)\nChain 3:                0.056 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 9e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.09 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.031 seconds (Warm-up)\nChain 4:                0.025 seconds (Sampling)\nChain 4:                0.056 seconds (Total)\nChain 4: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 1.2e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.12 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 1:                0.025 seconds (Sampling)\nChain 1:                0.05 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 8e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 2:                0.025 seconds (Sampling)\nChain 2:                0.05 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 7e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 3:                0.026 seconds (Sampling)\nChain 3:                0.052 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 8e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.023 seconds (Warm-up)\nChain 4:                0.024 seconds (Sampling)\nChain 4:                0.047 seconds (Total)\nChain 4: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 1.3e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.13 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.028 seconds (Warm-up)\nChain 1:                0.029 seconds (Sampling)\nChain 1:                0.057 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 8e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 2:                0.024 seconds (Sampling)\nChain 2:                0.049 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 8e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.027 seconds (Warm-up)\nChain 3:                0.026 seconds (Sampling)\nChain 3:                0.053 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 8e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.025 seconds (Warm-up)\nChain 4:                0.027 seconds (Sampling)\nChain 4:                0.052 seconds (Total)\nChain 4: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 1.2e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.12 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 1:                0.03 seconds (Sampling)\nChain 1:                0.056 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 8e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.027 seconds (Warm-up)\nChain 2:                0.028 seconds (Sampling)\nChain 2:                0.055 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 7e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 3:                0.025 seconds (Sampling)\nChain 3:                0.051 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 7e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.028 seconds (Warm-up)\nChain 4:                0.025 seconds (Sampling)\nChain 4:                0.053 seconds (Total)\nChain 4: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 1).\nChain 1: \nChain 1: Gradient evaluation took 1.3e-05 seconds\nChain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.13 seconds.\nChain 1: Adjust your expectations accordingly!\nChain 1: \nChain 1: \nChain 1: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 1: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 1: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 1: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 1: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 1: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 1: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 1: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 1: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 1: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 1: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 1: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 1: \nChain 1:  Elapsed Time: 0.029 seconds (Warm-up)\nChain 1:                0.034 seconds (Sampling)\nChain 1:                0.063 seconds (Total)\nChain 1: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 2).\nChain 2: \nChain 2: Gradient evaluation took 8e-06 seconds\nChain 2: 1000 transitions using 10 leapfrog steps per transition would take 0.08 seconds.\nChain 2: Adjust your expectations accordingly!\nChain 2: \nChain 2: \nChain 2: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 2: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 2: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 2: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 2: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 2: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 2: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 2: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 2: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 2: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 2: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 2: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 2: \nChain 2:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 2:                0.03 seconds (Sampling)\nChain 2:                0.056 seconds (Total)\nChain 2: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 3).\nChain 3: \nChain 3: Gradient evaluation took 7e-06 seconds\nChain 3: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 3: Adjust your expectations accordingly!\nChain 3: \nChain 3: \nChain 3: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 3: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 3: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 3: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 3: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 3: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 3: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 3: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 3: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 3: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 3: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 3: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 3: \nChain 3:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 3:                0.025 seconds (Sampling)\nChain 3:                0.051 seconds (Total)\nChain 3: \n\nSAMPLING FOR MODEL 'count' NOW (CHAIN 4).\nChain 4: \nChain 4: Gradient evaluation took 7e-06 seconds\nChain 4: 1000 transitions using 10 leapfrog steps per transition would take 0.07 seconds.\nChain 4: Adjust your expectations accordingly!\nChain 4: \nChain 4: \nChain 4: Iteration:    1 / 2000 [  0%]  (Warmup)\nChain 4: Iteration:  200 / 2000 [ 10%]  (Warmup)\nChain 4: Iteration:  400 / 2000 [ 20%]  (Warmup)\nChain 4: Iteration:  600 / 2000 [ 30%]  (Warmup)\nChain 4: Iteration:  800 / 2000 [ 40%]  (Warmup)\nChain 4: Iteration: 1000 / 2000 [ 50%]  (Warmup)\nChain 4: Iteration: 1001 / 2000 [ 50%]  (Sampling)\nChain 4: Iteration: 1200 / 2000 [ 60%]  (Sampling)\nChain 4: Iteration: 1400 / 2000 [ 70%]  (Sampling)\nChain 4: Iteration: 1600 / 2000 [ 80%]  (Sampling)\nChain 4: Iteration: 1800 / 2000 [ 90%]  (Sampling)\nChain 4: Iteration: 2000 / 2000 [100%]  (Sampling)\nChain 4: \nChain 4:  Elapsed Time: 0.026 seconds (Warm-up)\nChain 4:                0.031 seconds (Sampling)\nChain 4:                0.057 seconds (Total)\nChain 4: \n\nr &lt;- rbindlist(raw)\n\nr[deaths_n &gt; p95]\n\n     year age_cat deaths_n pop_jan1_n deaths_vs_pop_pr100000\n    &lt;num&gt;  &lt;char&gt;    &lt;num&gt;      &lt;num&gt;                  &lt;num&gt;\n 1:  2011 001_019      242    1183681               20.44470\n 2:  2019 001_019      161    1200066               13.41593\n 3:  2020 001_019      162    1193922               13.56873\n 4:  2021 001_019      153    1184656               12.91514\n 5:  2022 001_019      152    1178276               12.90020\n 6:  2023 001_019      193    1189436               16.22618\n 7:  2024 001_019      168    1191874               14.09545\n 8:  2022 020_039      672    1450705               46.32231\n 9:  2023 020_039      776    1467482               52.87969\n10:  2024 020_039      716    1483617               48.26043\n11:  2021 040_064     4519    1743406              259.20526\n12:  2022 040_064     4834    1750357              276.17223\n13:  2023 040_064     4641    1768614              262.40887\n14:  2024 040_064     4592    1786136              257.09129\n15:  2010 065_079    10567     502651             2102.25385\n16:  2019 065_079    11864     692842             1712.36732\n17:  2020 065_079    11950     711106             1680.48083\n18:  2021 065_079    12583     729335             1725.27028\n19:  2022 065_079    13794     749181             1841.21060\n20:  2023 065_079    13370     765101             1747.48171\n21:  2024 065_079    13565     779683             1739.80964\n22:  2012    080p    24848     221583            11213.85666\n23:  2022    080p    26225     240293            10913.75945\n     year age_cat deaths_n pop_jan1_n deaths_vs_pop_pr100000\n    year_frozen_at_2023       p5     p50      p95\n                  &lt;num&gt;    &lt;num&gt;   &lt;num&gt;    &lt;num&gt;\n 1:                2011   164.00   188.0   213.00\n 2:                2019   111.00   132.0   154.00\n 3:                2020   105.00   125.0   149.00\n 4:                2021    98.00   119.0   142.00\n 5:                2022    92.00   113.0   136.00\n 6:                2023    88.00   109.0   133.00\n 7:                2023    89.00   109.0   133.00\n 8:                2022   567.00   616.0   669.00\n 9:                2023   553.00   605.0   659.00\n10:                2023   558.00   611.0   666.00\n11:                2021  4187.00  4319.0  4455.05\n12:                2022  4067.00  4203.5  4344.05\n13:                2023  3974.00  4116.0  4263.00\n14:                2023  4009.00  4159.0  4303.00\n15:                2010 10102.00 10288.0 10488.00\n16:                2019 11415.00 11621.0 11822.00\n17:                2020 11460.95 11672.0 11887.00\n18:                2021 11479.00 11703.0 11933.00\n19:                2022 11520.00 11757.0 12008.05\n20:                2023 11498.95 11747.0 12006.00\n21:                2023 11717.00 11969.5 12237.05\n22:                2012 23957.00 24234.0 24523.05\n23:                2022 24255.00 24592.5 24935.05\n    year_frozen_at_2023       p5     p50      p95\n\nr[deaths_n &gt; p95 & year&gt;=2024]\n\n    year age_cat deaths_n pop_jan1_n deaths_vs_pop_pr100000 year_frozen_at_2023\n   &lt;num&gt;  &lt;char&gt;    &lt;num&gt;      &lt;num&gt;                  &lt;num&gt;               &lt;num&gt;\n1:  2024 001_019      168    1191874               14.09545                2023\n2:  2024 020_039      716    1483617               48.26043                2023\n3:  2024 040_064     4592    1786136              257.09129                2023\n4:  2024 065_079    13565     779683             1739.80964                2023\n      p5     p50      p95\n   &lt;num&gt;   &lt;num&gt;    &lt;num&gt;\n1:    89   109.0   133.00\n2:   558   611.0   666.00\n3:  4009  4159.0  4303.00\n4: 11717 11969.5 12237.05\n\nr[, age_pretty := fcase(\n  age_cat==\"000_000\", \"0\",\n  age_cat==\"001_019\", \"1-19\",\n  age_cat==\"020_039\", \"20-39\",\n  age_cat==\"040_064\", \"40-64\",\n  age_cat==\"065_079\", \"65-79\",\n  age_cat==\"080p\", \"80+\"\n)]\n\nq &lt;- ggplot(r[year&lt;=2024], aes(x = year))\nq &lt;- q + geom_ribbon(aes(ymin=100000*p5/pop_jan1_n, ymax=100000*p95/pop_jan1_n), fill = \"black\", alpha = 0.5)\nq &lt;- q + geom_line(aes(y = 100000*p50/pop_jan1_n))\nq &lt;- q + geom_point(aes(y = 100000*deaths_n/pop_jan1_n))\nq &lt;- q + geom_vline(xintercept = 2019.5, lty = 2, color = \"red\")\nq &lt;- q + facet_wrap(~age_pretty, scales = \"free\")\nq &lt;- q + scale_y_continuous(\"Deaths per 100k population\")\nq &lt;- q + scale_x_continuous(NULL, breaks = 2010:2024, minor_breaks = NULL)\nq &lt;- q + csstyle::set_x_axis_vertical()\nq &lt;- q + labs(\n  caption = \"Weekly baseline calculated from a poisson regression of 2010-2019.\\nData extracted from SSB table 10325\"\n)\nprint(q)"
  },
  {
    "objectID": "recipe/butter-chicken/butter-chicken.html",
    "href": "recipe/butter-chicken/butter-chicken.html",
    "title": "Butter Chicken",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n30min\n\n\nCooking time\n45min\n\n\nServes\nsix people"
  },
  {
    "objectID": "recipe/butter-chicken/butter-chicken.html#pudding",
    "href": "recipe/butter-chicken/butter-chicken.html#pudding",
    "title": "Butter Chicken",
    "section": "Pudding",
    "text": "Pudding\n\nSift together flour, bicarb soda, and salt.\nBeat sugar and eggs until light and fluffy.\nAdd apricot jam and beat well.\nIn a saucepan, melt the butter.\nAdd the vinegar and milk.\nFold in the flour and egg mixtures alternatively.\nPour into a greased baking tray.\nBake at 180C for 45 minutes."
  },
  {
    "objectID": "recipe/butter-chicken/butter-chicken.html#sauce",
    "href": "recipe/butter-chicken/butter-chicken.html#sauce",
    "title": "Butter Chicken",
    "section": "Sauce",
    "text": "Sauce\n\nPlace all ingredients into a saucepan.\nStir over moderate heat until butter has melted and the sugar dissolved.\nPierce pudding with skewer and pour sauce over hot pudding."
  },
  {
    "objectID": "recipe/butter-chicken/butter-chicken.html#serving",
    "href": "recipe/butter-chicken/butter-chicken.html#serving",
    "title": "Butter Chicken",
    "section": "Serving",
    "text": "Serving\n\nGarnish with fresh mint leaves.\nServe hot or cold with cream or custard."
  },
  {
    "objectID": "recipe/flat-bread/flat-bread.html",
    "href": "recipe/flat-bread/flat-bread.html",
    "title": "Flat Bread",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n1h\n\n\nCooking time\n10min\n\n\nServes\nXXkg loaf of bread\n\n\n\n\nIngredients\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nDough\nWater\n320g\n\n\n\nYeast\n15g\n\n\n\nFlour\n500g\n\n\n\nSalt\n10g\n\n\n\nOlive oil\n50g\n\n\n\n\n\nInstructions\n\nCombine all ingredients.\nKnead.\nCover and leave to rise for 30 minutes.\nFlatten with fingers and place in pan.\nCover and leave to rise for 20 minutes\nFlatten with fingers.\nLeave to rise for 10 minutes\nPlace covered in oven and fan-bake at 220 for 10 minutes (soft) or 15 minutes (crisp)."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html",
    "href": "recipe/malva-pudding/malva-pudding.html",
    "title": "Malva Pudding",
    "section": "",
    "text": "Information\n\n\nMetric\nValue\n\n\n\n\nPrep time\n30min\n\n\nCooking time\n45min\n\n\nServes\nsix people"
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#pudding-flour-mix",
    "href": "recipe/malva-pudding/malva-pudding.html#pudding-flour-mix",
    "title": "Malva Pudding",
    "section": "Pudding (flour mix)",
    "text": "Pudding (flour mix)\n\nSift together flour, bicarb soda, and salt."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#pudding-egg-mix",
    "href": "recipe/malva-pudding/malva-pudding.html#pudding-egg-mix",
    "title": "Malva Pudding",
    "section": "Pudding (egg mix)",
    "text": "Pudding (egg mix)\n\nBeat sugar and eggs until light and fluffy.\nAdd apricot jam and beat well."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#pudding-i",
    "href": "recipe/malva-pudding/malva-pudding.html#pudding-i",
    "title": "Malva Pudding",
    "section": "Pudding (I)",
    "text": "Pudding (I)\n\nIn a saucepan, melt the butter.\nAdd the vinegar and milk.\nFold in the flour and egg mixtures alternatively.\nPour into a greased baking tray.\nBake at 180C for 45 minutes."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#sauce",
    "href": "recipe/malva-pudding/malva-pudding.html#sauce",
    "title": "Malva Pudding",
    "section": "Sauce",
    "text": "Sauce\n\nPlace all ingredients into a saucepan.\nStir over moderate heat until butter has melted and the sugar dissolved."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#pudding-ii",
    "href": "recipe/malva-pudding/malva-pudding.html#pudding-ii",
    "title": "Malva Pudding",
    "section": "Pudding (II)",
    "text": "Pudding (II)\n\nPierce pudding with skewer and pour sauce over hot pudding."
  },
  {
    "objectID": "recipe/malva-pudding/malva-pudding.html#serving",
    "href": "recipe/malva-pudding/malva-pudding.html#serving",
    "title": "Malva Pudding",
    "section": "Serving",
    "text": "Serving\n\nGarnish with fresh mint leaves.\nServe hot or cold with cream or custard."
  },
  {
    "objectID": "recipe/sourdough/sourdough.html",
    "href": "recipe/sourdough/sourdough.html",
    "title": "Sourdough",
    "section": "",
    "text": "Figure 1: A 1,3 kg loaf of sourdough.\n\n\n\n\n\n\n\n\n\n\n\nFigure 2: Sliced bread.\n\n\n\n\n\n\n\nInformation\n\n\nMetric\nValue\n\n\n\n\nPrep time\n12-24h\n\n\nCooking time\n1,5h\n\n\nServes\n1,3kg loaf of bread\n\n\n\n\nIngredients\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nLevain\nSourdough starter\n30g\n\n\n\nWater\n60g\n\n\n\nFlour\n60g\n\n\n\nYeast\n4g\n\n\n\n\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nDough\nFlour\n750g\n\n\n\nWater\n550g\n\n\n\nSalt\n15g\n\n\n\nMSG\n5g\n\n\n\n\n\n\n\nPurpose\nIngredient\nQuantity\n\n\nOven steam\nWater in metal container\n250mL\n\n\n\n\n\nInstructions\nTest"
  },
  {
    "objectID": "recipes.html",
    "href": "recipes.html",
    "title": "Recipes",
    "section": "",
    "text": "Title\n\n\nDescription\n\n\n\n\n\n\nButter Chicken\n\n\nNorth Indian curry with butter, yoghurt, and chicken. \n\n\n\n\nChallah\n\n\nYeast-risen egg bread. \n\n\n\n\nFlat Bread\n\n\nBasic olive flat bread. \n\n\n\n\nHummus\n\n\nA simple sourdough method. \n\n\n\n\nMalva Pudding\n\n\nA sweet South African pudding. \n\n\n\n\nPalak Paneer\n\n\nNorth Indian curry with paneer and spinach. \n\n\n\n\nSourdough\n\n\nA simple sourdough method. \n\n\n\n\nWhite Bread\n\n\nBasic white bread. \n\n\n\n\n\nNo matching items"
  }
]